Methods for sonogenetic stimulation of cells expressing heterologous mechanosensitive proteins
Patent Information
- Application Number
- JP2023528009
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-11
- Filing Date
- 2021-11-10
- Publication Date
- 2024-11-15
AI Technical Summary
Existing methods for manipulating neural activity, particularly in deeper brain regions, face challenges due to difficulties in delivering stimuli to target neurons, necessitating the development of non-invasive techniques for neuronal manipulation.
The use of mechanosensory polypeptides, such as DmFLYC1, DmFLYC2, DcFLYC1.1, DcFLYC1.2, and DmOSCA, expressed in cells and activated by ultrasound to induce cation or anion influx/efflux, modulating cellular activity and function.
This approach allows for non-invasive modulation of neural activity by applying ultrasound, effectively influencing cellular responses and functions in neurons, including those in deeper brain regions.
Smart Images

Figure 00000068_0000 
Figure 00000068_0001 
Figure 00000069_0000
Abstract
Description
[Technical Field]
[0001] Cross-reference of related applications This application claims priority and interest in Provisional Patent Application No. 63 / 112,256, filed on November 11, 2020, the entire contents of which are incorporated herein by reference.
[0002] Statements concerning the rights to inventions made under research supported by the federal government. This invention was made with government support under Grant Numbers MH111534, NS115591, 5R35GM122604, HL143297, P30014195, CA014195, NS072031, and F32GM101876, awarded by the National Institutes of Health, and Grant Numbers DBI-0735191, DBI-1265383, and DBI-1743442, awarded by the National Science Foundation. The government has certain rights in this invention.
[0003] Sequence List This application includes a sequence listing submitted electronically in ASCII format, the entirety of which is incorporated herein by reference. The ASCII copy, created on October 29, 2021, is named 167776-011601PCT_SL.txt and is 64,961 bytes in size. [Background technology]
[0004] background Understanding how neural circuits produce specific behaviors requires the ability to identify participating neurons and record or disrupt their activity patterns. The crab gastric ganglia (STG), one of the best-understood motor circuits, benefits from electrophysiological access to clearly defined cell types and the ability to manipulate them. Numerous approaches have been developed to manipulate neural activity using light (optogenetics) or small molecules. While these methods have revealed insights into circuit computation in many model systems, including mice, they have drawbacks, such as the difficulty in delivering stimuli to target neurons located in deeper brain regions. Therefore, there remains a need for new products and methods for non-invasive manipulation of target neurons and other cell types. [Overview of the project]
[0005] overview Products and compositions characterized by mechanesensory polypeptides and polynucleotides, methods for expressing such polypeptides and polynucleotides in a target cell type, and methods for inducing the activation of mechanesensory polypeptides in neurons and other cell types using ultrasound are provided and characterized herein.
[0006] In one embodiment, a method is provided for inducing the influx or efflux of cations or anions in a cell, and this method is The process involves expressing a heterogeneous mechanesensory polypeptide selected from one or more of the following in cells: DmFLYC1, DmFLYC2, DcFLYC1.1, DcFLYC1.2, and DmOSCA, and The process involves applying ultrasound to cells, thereby inducing the influx or outflow of cations or anions in the cells.
[0007] In another embodiment, a method is provided for initiating a cellular response to mechanical deformation or stretching caused by ultrasound, the method being A step of transducing cells to express a heterologous mechanesensory polypeptide selected from one or more of the following: DmFLYC1, DmFLYC2, DcFLYC1.1, DcFLYC1.2, and DmOSCA. The process of applying ultrasound to cells, and The process involves, after the application of ultrasound, inducing the influx or outflow of cations or anions, and changes in cell activity and / or function, in cells expressing mechanesensible polypeptides, thereby initiating a cellular response to mechanical deformation or stretching caused by ultrasound.
[0008] In another embodiment, a method is provided for regulating cell activity and / or function by inducing a cellular response to mechanical deformation or stretching caused by ultrasound, the method being A step of transducing cells to express a heterologous mechanesensory polypeptide selected from one or more of the following: DmFLYC1, DmFLYC2, DcFLYC1.1, DcFLYC1.2, and DmOSCA. A step of applying ultrasound to cells expressing mechanesensory polypeptides, and The process involves, after the application of ultrasound, inducing the influx or outflow of cations or anions in cells expressing mechanesensible polypeptides, and inducing changes in cell activity and / or function, thereby inducing a cellular response to mechanical deformation or stretching caused by ultrasound, and thereby regulating cell activity and / or function.
[0009] In one embodiment of the above method, the heterogeneous mechanesensible polypeptide is a variant of the DmFLYC1 polypeptide. In one embodiment, the variant is the R334E FLYC1 variant polypeptide. In the embodiment, the R334E FLYC1 variant polypeptide comprises an amino acid sequence having at least 85% or at least 95% sequence identity with respect to the sequence of SEQ ID NO: 42. In one embodiment, the R334E FLYC1 variant polypeptide comprises or essentially consists of SEQ ID NO: 42. In any embodiment of the above aspects, the cell is sensitized to mechanical deformation or stretching induced by ultrasound. In any embodiment of the above aspects, the application of ultrasound results in a change in the mechanesensible polypeptide conductance in the cell, thereby regulating cell activity and / or function.
[0010] In any one of the above-described embodiments and their embodiments, applying ultrasonic waves induces the influx or efflux of anions in cells. In some embodiments, applying ultrasonic waves induces an anion influx that inhibits or suppresses the activity and / or function of cells. In some embodiments, applying ultrasonic waves induces an anion efflux that evokes or stimulates the activity and / or function of plant cells. In some embodiments, the polypeptide is selected from one or more of the following: DmFLYC1, DmFLYC2, DcFLYC1.1, and DcFLYC1.2. In some embodiments, the polypeptide comprises a sequence having at least 85% sequence identity to a polypeptide sequence selected from SEQ ID NO: 5, 7, 11, 13, or 42. In some embodiments, the polypeptide is encoded by a sequence having at least 85% sequence identity to a polynucleotide sequence selected from SEQ ID NO: 6, 8, 12, or 14. In some embodiments, the polypeptide is encoded by a sequence having at least 95% sequence identity to a polynucleotide sequence selected from SEQ ID NO: 6, 8, 12, or 14. In some embodiments, the polypeptide comprises or consists essentially of a polypeptide sequence selected from SEQ ID NO: 6, 8, 12, or 14.
[0011] In some embodiments of the above aspects and their embodiments, the application of ultrasound induces cation influx into cells. In some embodiments, cation influx increases cell activity. In some embodiments, the polypeptide is DmOSCA. In some embodiments, the polypeptide contains a sequence having at least 85% sequence identity to SEQ ID NO: 9. In some embodiments, the polypeptide contains a sequence having at least 95% sequence identity to SEQ ID NO: 9. In some embodiments, the polypeptide contains or essentially consists of the sequence of SEQ ID NO: 9. In some embodiments, the polypeptide is encoded by a polynucleotide sequence having at least 85% sequence identity to SEQ ID NO: 10. In some embodiments, the polypeptide is encoded by a polynucleotide sequence having at least 95% sequence identity to SEQ ID NO: 10. In some embodiments, the polypeptide is encoded by a polynucleotide sequence containing or essentially consisting of SEQ ID NO: 10.
[0012] In one embodiment of any of the above aspects and their embodiments, the polypeptide is encoded by a polynucleotide sequence codon-optimized for expression in mammalian or human cells and is not naturally occurring. In one embodiment of any of the above aspects and their embodiments, the polypeptide is expressed intracellularly after transduction of cells with a plasmid or viral vector containing a polynucleotide sequence encoding the polypeptide. In one embodiment of any of the above aspects and their embodiments, the cells are transduced with a viral vector selected from a lentiviral vector or an adeno-associated virus (AAV) vector. In one embodiment of any of the above aspects and their embodiments, the cells are mammalian cells. In one embodiment of any of the above aspects and their embodiments, the cells are human cells. In one embodiment of any of the above aspects and their embodiments, the cells are one or more of muscle cells, cardiomyocytes, insulin-secreting cells, pancreatic cells, kidney cells, or nerve cells. In one embodiment, the cells are nerve cells. In one embodiment, the cells are plant cells, and anion efflux and / or stimulation of plant cell activity or function is induced by application of ultrasound to the cells. In one embodiment, the cells are in vitro, ex vivo, or in vivo.
[0013] In one embodiment of any of the above aspects and their embodiments, the ultrasound has a frequency of from about 0.2 MHz to about 20 MHz. In one embodiment of any of the above aspects and their embodiments, the ultrasound has a focal zone of from about 1 cubic millimeter to about 1 cubic centimeter. In one embodiment, any of the methods of the above aspects can further involve contacting the cells with microbubbles prior to applying the ultrasound.
[0014] In one embodiment of any of the above aspects and their embodiments, the cells are within a subject. In one embodiment, the subject is a mammal. In one embodiment, the subject is a human.
[0015] In the above embodiments and any one of their embodiments, ultrasound is generated using a photoacoustic system or a transducer. In the above embodiments and any one of their embodiments, ultrasound is generated using a lead zirconate titanate (PZT) transducer.
[0016] In another embodiment, a plasmid or viral vector is provided containing a polynucleotide encoding a mechanosensible polypeptide selected from one or more of the following: DmFLYC1, DmFLYC2, DcFLYC1.1, DcFLYC1.2, DmOSCA, or their variants. In one embodiment, the mechanosensible polypeptide is a variant of the DmFLYC1 polypeptide. In one embodiment, the variant is the R334E FLYC1 variant polypeptide. In one embodiment, the R334E FLYC1 variant polypeptide comprises an amino acid sequence having at least 85% or at least 95% sequence identity with respect to the sequence of SEQ ID NO: 42. In one embodiment, the R334E FLYC1 variant polypeptide comprises or essentially consists of SEQ ID NO: 42.
[0017] In another embodiment, cells are provided comprising a plasmid or viral vector as described above, or a heterogeneous gene sequence encoding a polypeptide selected from one or more of the following: DmFLYC1, DmFLYC2, DcFLYC1.1, DcFLYC1.2, and DmOSCA, or their variants. In one embodiment, the encoded polypeptide is a variant of the DmFLYC1 polypeptide. In one embodiment, the variant is the R334E FLYC1 variant polypeptide. In an embodiment, the R334E FLYC1 variant polypeptide comprises an amino acid sequence having at least 85% or at least 95% sequence identity with respect to the sequence of SEQ ID NO: 42. In some embodiments, the R334E FLYC1 variant polypeptide comprises or essentially consists of SEQ ID NO: 42.
[0018] In one embodiment, the vector is a viral vector, which is a lentiviral vector or an adeno-associated virus (AAV) vector.
[0019] In any of the above embodiments and their embodiments, the polypeptide includes a sequence having at least 85% sequence identity to a polypeptide sequence selected from one or more of SEQ ID NOs: 5, 7, 11, 13, or 9. In any of the above embodiments and their embodiments, the polypeptide includes a sequence having at least 95% sequence identity to a polypeptide sequence selected from one or more of SEQ ID NOs: 5, 7, 11, 13, or 9. In any of the above embodiments and their embodiments, the polypeptide includes a sequence that includes, or essentially consists of, a sequence selected from one or more of SEQ ID NOs: 5, 7, 11, 13, or 9. In any of the above embodiments and their embodiments, the polypeptide is encoded by a sequence having at least 85% sequence identity to a polynucleotide sequence selected from one or more of SEQ ID NOs: 6, 8, 12, 14, or 10. In any of the above embodiments and their embodiments, the polypeptide is encoded by a sequence having at least 95% sequence identity to a polynucleotide sequence selected from one or more of SEQ ID NOs: 6, 8, 12, 14, or 10. In any of the above embodiments and their embodiments, the polypeptide comprises or is encoded by a sequence consisting of a polynucleotide sequence selected from one or more of SEQ ID NOs: 6, 8, 12, 14, or 10.
[0020] In any of the above embodiments and their embodiments, the cells are plant cells, and anion efflux and / or stimulation of plant cell activity or function is induced by the application of ultrasound to the cells. In any of the above embodiments and their embodiments, the cells are mammalian cells. In any of the above embodiments and their embodiments, the cells are human cells. In any of the above embodiments and their embodiments, the cells are one or more of muscle cells, cardiomyocytes, insulin-secreting cells, pancreatic cells, kidney cells, or nerve cells. In one embodiment, the cells are nerve cells.
[0021] In another embodiment, an isolated polynucleotide encoding the mechanosensible DmFLYC1 polypeptide or a variant thereof is provided. In another embodiment, an isolated polynucleotide encoding the mechanosensible DmFLYC2 polypeptide is provided. In another embodiment, an isolated polynucleotide encoding the mechanosensible DcFLYC1.1 polypeptide is provided. In another embodiment, an isolated polynucleotide encoding the mechanosensible DcFLYC1.2 polypeptide is provided. In another embodiment, an isolated polynucleotide encoding the mechanosensible DmOSCA polypeptide is provided.
[0022] In a further embodiment, a mechanesensible polypeptide is provided, encoded by any one of the above embodiments and their embodiments. In another embodiment, a plasmid or viral vector is provided, containing an isolated polynucleotide from any one of the above embodiments and their embodiments.
[0023] In one embodiment, cells are provided containing an isolated polynucleotide of any one of the above embodiments and their embodiments. In another embodiment, cells are provided expressing a mechanesensible polypeptide of any one of the above embodiments and their embodiments.
[0024] In another embodiment, a composition is provided comprising cells from any of the embodiments described above. In one embodiment, the composition further comprises a pharmaceutically acceptable carrier, excipient, or diluent.
[0025] In the above embodiments and any one of their embodiments, the isolated polynucleotide is codon-optimized for expression in mammalian cells. In the above embodiments and any one of their embodiments, the isolated polynucleotide is codon-optimized for expression in human cells.
[0026] In any of the above embodiments and their embodiments, the polypeptide is DmFLYC1 comprising a sequence having at least 85% sequence identity with SEQ ID NO: 5 or SEQ ID NO: 42. In any of the above embodiments and their embodiments, the polypeptide is DmFLYC1 comprising a sequence having at least 95% sequence identity with SEQ ID NO: 5 or SEQ ID NO: 42. In any of the above embodiments and their embodiments, the polypeptide is DmFLYC1 comprising or essentially comprising SEQ ID NO: 5 or SEQ ID NO: 42. In any of the above embodiments and their embodiments, the polypeptide is encoded by a polynucleotide sequence having at least 85% sequence identity with SEQ ID NO: 6. In any of the above embodiments and their embodiments, the polypeptide is encoded by a polynucleotide sequence having at least 95% sequence identity with SEQ ID NO: 6. In any of the above embodiments and their embodiments, the polypeptide is encoded by a polynucleotide sequence comprising or essentially comprising SEQ ID NO: 6.
[0027] In any of the above embodiments and their embodiments, the polypeptide is DmFLYC2 and includes a sequence having at least 85% or at least 95% sequence identity with respect to SEQ ID NO: 7. In any of the above embodiments and their embodiments, the polypeptide is DmFLYC2 that includes or essentially consists of SEQ ID NO: 7. In any of the above embodiments and their embodiments, the polypeptide is encoded by a polynucleotide sequence having at least 85% or at least 95% sequence identity with respect to SEQ ID NO: 8. In any of the above embodiments and their embodiments, the polypeptide is encoded by a polynucleotide sequence that includes or essentially consists of SEQ ID NO: 8.
[0028] In any of the above embodiments and their embodiments, the polypeptide is DcFLYC1.1 and comprises a sequence having at least 85% or at least 95% sequence identity with SEQ ID NO: 11. In any of the above embodiments and their embodiments, the polypeptide is DcFLYC1.1 comprising or essentially comprising SEQ ID NO: 11. In any of the above embodiments and their embodiments, the polypeptide is encoded by a polynucleotide sequence having at least 85% or at least 95% sequence identity with SEQ ID NO: 12. In any of the above embodiments and their embodiments, the polypeptide is encoded by a polynucleotide sequence comprising or essentially comprising SEQ ID NO: 12.
[0029] In any of the above embodiments and their embodiments, the polypeptide is DcFLYC1.2 and includes a sequence having at least 85% or at least 95% sequence identity with SEQ ID NO: 13. In any of the above embodiments and their embodiments, the polypeptide is DcFLYC1.2 that includes or essentially consists of SEQ ID NO: 13. In any of the above embodiments and their embodiments, the polypeptide is encoded by a polynucleotide sequence having at least 85% or at least 95% sequence identity with SEQ ID NO: 14. In any of the above embodiments and their embodiments, the polypeptide is encoded by a polynucleotide sequence that includes or essentially consists of SEQ ID NO: 14.
[0030] In any of the above embodiments and their embodiments, the polypeptide is DmOSCA and comprises a sequence having at least 85% or at least 95% sequence identity with SEQ ID NO: 9. In any of the above embodiments and their embodiments, the polypeptide is DmOSCA comprising or essentially comprising SEQ ID NO: 9. In any of the above embodiments and their embodiments, the polypeptide is encoded by a polynucleotide sequence having at least 85% or at least 95% sequence identity with SEQ ID NO: 10. In any of the above embodiments and their embodiments, the polypeptide is encoded by a polynucleotide sequence comprising or essentially comprising SEQ ID NO: 10.
[0031] In the above embodiments and any one embodiment thereof, the polypeptide is DmFLYC1. In the above embodiments and any one embodiment thereof, the DmFLYC1 polypeptide is encoded by a polynucleotide sequence that includes or essentially consists of SEQ ID NO: 5, or that includes or essentially consists of SEQ ID NO: 42.
[0032] In any one embodiment of the above embodiments, the anion inflow or outflow is a chloride anion inflow or outflow.
[0033] The compositions and articles defined by the embodiments and models described herein were isolated or otherwise manufactured in connection with the examples provided herein. Other features and advantages of the embodiments and models provided herein will become apparent from the detailed description and the claims.
[0034] definition Unless otherwise defined, technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art. See, for example, Singleton et al., DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY 2nd ed., J. Wiley & Sons (New York, NY 1994) and Sambrook et al., MOLECULAR CLONING, A LABORATORY MANUAL, Cold Spring Harbor Press (Cold Spring Harbor, NY 1989). Any methods, devices, and materials similar to or equivalent to those described herein may be used in carrying out the embodiments and models described herein. The following definitions are provided to facilitate the understanding of certain terms frequently used herein and are not intended to limit the scope of this disclosure.
[0035] "FLYC1" or "DmFLYC1" means a mechanosensory polypeptide that can confer ultrasound sensitivity to cells, such as neurons, and have at least about 85% amino acid sequence identity to the DmFLYC1 polypeptide sequence, fragment thereof, or its human ortholog provided below, and have the biological activity described herein. In embodiments, the mechanosensory polypeptide has at least about 90%, at least about 95%, or at least about 98% amino acid sequence identity to the DmFLYC1 polypeptide sequence, fragment thereof, or its human ortholog provided below, and has the biological activity described herein. In some embodiments, the DmFLYC1 polypeptide is substantially identical to the DmFLYC1 polypeptide sequence provided below, or a functional variant, isoform, homolog, or ortholog having substantial identity thereto. In some embodiments, the DmFLYC1 polypeptide is a functional homolog, isoform, ortholog, or fragment of the DmFLYC1 polypeptide sequence provided below. In some embodiments, the FLYC1 polypeptide, heterologously expressed in cells such as fibroblasts and insulin-secreting (INS) cells, inhibits cells upon ultrasound (US) stimulation. In some embodiments, the DmFLYC1 polypeptide is or comprises the DmFLYC1 polypeptide sequence provided immediately below.
[0036] DmFLYC1 polypeptide sequence: TIFF2023549176000001.tif93149.
[0037] In one embodiment, a variant of the FLYC1 polypeptide, i.e., the "R334E variant," is provided in which the amino acid arginine (R) at position 334 is replaced with the amino acid glutamic acid (E). The "R" amino acid that has been changed to "E" at position 334 of the FLYC1 amino acid sequence is shown in bold and underlined in the above DmFLYC1 polypeptide sequence. The amino acid sequence of the FLYC1R334E polypeptide variant containing "E" at position 334 is shown below. The variant "E" at position 334 is shown in bold and underlined in the sequence below. TIFF2023549176000002.tif94151
[0038] "DmFLYC1 polynucleotide" or "FLYC1 polynucleotide" means a nucleic acid molecule encoding the DmFLYC1 polypeptide. In certain embodiments, the codons of the DmFLYC1 polynucleotide are optimized for expression in the organism of interest or in the cells of the organism of interest (e.g., optimized for human expression or expression in human cells, mammalian expression or expression in mammalian cells, plant expression or expression in plant cells). Exemplary DmFLYC1 polynucleotide sequences are provided immediately below. In some embodiments, the DmFLYC1 nucleic acid molecule is substantially identical to the DmFLYC1 nucleic acid molecule provided below, or a functional variant, ortholog, or homolog having substantial identity thereto. In some embodiments, the DmFLYC1 nucleic acid molecule is a nucleic acid molecule having the DmFLYC1 polynucleotide sequence provided below. In some embodiments, the DmFLYC1 nucleic acid molecule is a functional homolog, isoform, or fragment of a nucleic acid molecule having the sequence provided below. In some embodiments, the DmFLYC1 nucleic acid molecule is or comprises the DmFLYC1 polynucleotide sequence provided immediately below. In some embodiments, for example, for expression in mammalian cells, e.g., human cells, the codon-optimized DmFLYC1 polynucleotide sequence provided below is used, or a sequence having at least 85% sequence identity thereto is used. In embodiments, sequences having at least 90%, at least 95%, or at least 98% sequence identity are used.
[0039] DmFLYC1 polynucleotide sequence (DmFLYC1 codon-optimized polynucleotide sequence):
[0040] "FLYC2" or "DmFLYC2" means a mechanosensory polypeptide that can confer ultrasound sensitivity to cells, such as neurons, and have at least about 85% amino acid sequence identity to the DmFLYC2 polypeptide sequence, fragment thereof, or its human ortholog provided below, and have the biological activity described herein. In embodiments, the mechanosensory polypeptide has at least about 90%, at least about 95%, or at least about 98% amino acid sequence identity to the DmFLYC2 polypeptide sequence, fragment thereof, or its human ortholog provided below, and has the biological activity described herein. In some embodiments, the DmFLYC2 polypeptide is substantially identical to the DmFLYC2 polypeptide sequence provided below, or a functional variant, isoform, homolog, or ortholog having substantial identity thereto. In some embodiments, the DmFLYC2 polypeptide is a functional homolog, isoform, ortholog, or fragment of the DmFLYC2 polypeptide sequence provided below. In some embodiments, the DmFLYC2 polypeptide is or comprises the DmFLYC2 polypeptide sequence provided immediately below.
[0041] DmFLYC2 polypeptide sequence: (Sequence ID 7).
[0042] "DmFLYC2 polynucleotide" or "FLYC2 polynucleotide" means a nucleic acid molecule encoding the DmFLYC2 polypeptide. In certain embodiments, the codons of the DmFLYC2 polynucleotide are optimized for expression in the organism of interest or in the cells of the organism of interest (e.g., optimized for human expression or expression in human cells, mammalian expression or expression in mammalian cells, plant expression or expression in plant cells). Exemplary DmFLYC2 polynucleotide sequences are provided immediately below. In some embodiments, the DmFLYC2 nucleic acid molecule is substantially identical to the DmFLYC2 nucleic acid molecule provided below, or a functional variant, ortholog, or homolog having substantial identity thereto. In some embodiments, the DmFLYC2 nucleic acid molecule is a nucleic acid molecule having the DmFLYC2 polynucleotide sequence provided below. In some embodiments, the DmFLYC2 nucleic acid molecule is a functional homolog, isoform, or fragment of a nucleic acid molecule having the sequence provided below. In some embodiments, the DmFLYC2 nucleic acid molecule is or comprises the DmFLYC2 polynucleotide sequence provided immediately below. In some embodiments, for example, for expression in mammalian cells, e.g., human cells, the codon-optimized DmFLYC2 polynucleotide sequence provided below is used, or a sequence having at least 85% sequence identity thereto is used. In embodiments, sequences having at least 90%, at least 95%, or at least 98% sequence identity are used.
[0043] DmFLYC2 polynucleotide sequence (DmFLYC2 codon-optimized polynucleotide sequence):
[0044] "DmOSCA" means a mechanosensory polypeptide that can confer ultrasound sensitivity to cells, such as neurons, and have at least about 85% amino acid sequence identity to the DmOSCA polypeptide sequence, fragment thereof, or its human ortholog provided below, and have the biological activity described herein. In embodiments, the mechanosensory polypeptide has at least about 90%, at least about 95%, or at least about 98% amino acid sequence identity to the DmOSCA polypeptide sequence, fragment thereof, or its human ortholog provided below, and has the biological activity described herein. In some embodiments, the DmOSCA polypeptide is substantially identical to the DmOSCA polypeptide sequence provided below, or a functional variant, isoform, homolog, or ortholog having substantial identity thereto. In some embodiments, the DmOSCA polypeptide is a functional homolog, isoform, ortholog, or fragment of the DmOSCA polypeptide sequence provided below. In some embodiments, the DmOSCA polypeptide is or includes the DmOSCA polypeptide sequence provided immediately below.
[0045] DmOSCA polypeptide sequence: (Sequence ID 9).
[0046] "DmOSCA polynucleotide" means a nucleic acid molecule encoding a DmOSCA polypeptide. In certain embodiments, the codons of the DmOSCA polynucleotide are optimized for expression in the organism of interest or in the cells of the organism of interest (e.g., optimized for human expression or expression in human cells, mammalian expression or expression in mammalian cells, plant expression or expression in plant cells). Exemplary DmOSCA polynucleotide sequences are provided immediately below. In some embodiments, the DmOSCA nucleic acid molecule is substantially identical to the DmOSCA nucleic acid molecule provided below, or a functional variant, ortholog, or homolog having substantial identity thereto. In some embodiments, the DmOSCA nucleic acid molecule is a nucleic acid molecule having the DmOSCA polynucleotide sequence provided below. In some embodiments, the DmOSCA nucleic acid molecule is a functional homolog, isoform, or fragment of a nucleic acid molecule having the sequence provided below. In some embodiments, the DmOSCA nucleic acid molecule is or contains the DmOSCA polynucleotide sequence provided immediately below. In some embodiments, for example, for expression in mammalian cells, such as human cells, the codon-optimized DmOSCA polynucleotide sequence provided below is used, or a sequence having at least 85% sequence identity thereto is used. In embodiments, sequences having at least 90%, at least 95%, or at least 98% sequence identity are used.
[0047] DmOSCA polynucleotide sequences (DmOSCA codon-optimized polynucleotide sequences):
[0048] "DcFLYC1.1" means a mechanosensory polypeptide that can confer ultrasound sensitivity to cells, such as neurons, and have at least about 85% amino acid sequence identity to the DcFLYC1.1 polypeptide sequence, fragment thereof, or its human ortholog provided below, and have the biological activity described herein. In embodiments, the mechanosensory polypeptide has at least about 90%, at least about 95%, or at least about 98% amino acid sequence identity to the DcFLYC1.1 polypeptide sequence, fragment thereof, or its human ortholog provided below, and has the biological activity described herein. In some embodiments, the DcFLYC1.1 polypeptide is substantially identical to the DcFLYC1.1 polypeptide sequence, or a functional variant, isoform, homolog, or ortholog having substantial identity thereto, provided below. In some embodiments, the DcFLYC1.1 polypeptide is a functional homolog, isoform, ortholog, or fragment of the DcFLYC1.1 polypeptide sequence provided below. In some embodiments, the DcFLYC1.1 polypeptide is or comprises the DcFLYC1.1 polypeptide sequence provided immediately below.
[0049] DcFLYC1.1 polypeptide sequence: (Sequence ID 11).
[0050] "DcFLYC1.1 polynucleotide" means a nucleic acid molecule encoding the DcFLYC1.1 polypeptide. In certain embodiments, the codons of the DcFLYC1.1 polynucleotide are optimized for expression in the organism of interest or in the cells of the organism of interest (e.g., optimized for human expression or expression in human cells, mammalian expression or expression in mammalian cells, plant expression or expression in plant cells). Exemplary DcFLYC1.1 polynucleotide sequences are provided immediately below. In some embodiments, the DcFLYC1.1 nucleic acid molecule is substantially identical to the DcFLYC1.1 nucleic acid molecule provided below, or a functional variant, ortholog, or homolog having substantial identity thereto. In some embodiments, the DcFLYC1.1 nucleic acid molecule is a nucleic acid molecule having the DcFLYC1.1 polynucleotide sequence provided below. In some embodiments, the DcFLYC1.1 nucleic acid molecule is a functional homolog, isoform, or fragment of a nucleic acid molecule having the sequence provided below. In some embodiments, the DcFLYC1.1 nucleic acid molecule is or comprises the DcFLYC1.1 polynucleotide sequence provided immediately below. In some embodiments, for example, for expression in mammalian cells, e.g., human cells, the codon-optimized DcFLYC1.1 polynucleotide sequence provided below is used, or a sequence having at least 85% sequence identity thereto is used. In embodiments, sequences having at least 90%, at least 95%, or at least 98% sequence identity are used.
[0051] DcFLYC1.1 polynucleotide sequence (DcFLYC1.1 codon-optimized polynucleotide sequence):
[0052] "DcFLYC1.2" means a mechanesensible polypeptide that can confer ultrasound sensitivity to cells, such as neurons, and have at least about 85% amino acid sequence identity to the DcFLYC1.2 polypeptide sequence, fragment thereof, or its human ortholog provided below, and have the biological activity described herein. In embodiments, the mechanesensible polypeptide has at least about 90%, at least about 95%, or at least about 98% amino acid sequence identity to the DcFLYC1.2 polypeptide sequence, fragment thereof, or its human ortholog provided below, and has the biological activity described herein. In some embodiments, the DcFLYC1.2 polypeptide is substantially identical to the DcFLYC1.2 polypeptide sequence, or a functional variant, isoform, homolog, or ortholog having substantial identity thereto, provided below. In some embodiments, the DcFLYC1.2 polypeptide is a functional homolog, isoform, ortholog, or fragment of the DcFLYC1.2 polypeptide sequence provided below. In some embodiments, the DcFLYC1.2 polypeptide is or comprises the DcFLYC1.2 polypeptide sequence provided immediately below.
[0053] DcFLYC1.2 polypeptide sequence: (Sequence ID 13).
[0054] "DcFLYC1.2 polynucleotide" means a nucleic acid molecule encoding the DcFLYC1.2 polypeptide. In certain embodiments, the codons of the DcFLYC1.2 polynucleotide are optimized for expression in the organism of interest or in the cells of the organism of interest (e.g., optimized for human expression or expression in human cells, mammalian expression or expression in mammalian cells, plant expression or expression in plant cells). Exemplary DcFLYC1.2 polynucleotide sequences are provided immediately below. In some embodiments, the DcFLYC1.2 nucleic acid molecule is substantially identical to the DcFLYC1.2 nucleic acid molecule provided below, or a functional variant, ortholog, or homolog having substantial identity thereto. In some embodiments, the DcFLYC1.2 nucleic acid molecule is a nucleic acid molecule having the DcFLYC1.2 polynucleotide sequence provided below. In some embodiments, the DcFLYC1.2 nucleic acid molecule is a functional homolog, isoform, or fragment of a nucleic acid molecule having the sequence provided below. In some embodiments, the DcFLYC1.2 nucleic acid molecule is or comprises the DcFLYC1.2 polynucleotide sequence provided immediately below. In some embodiments, for example, for expression in mammalian cells, e.g., human cells, the codon-optimized DcFLYC1.2 polynucleotide sequence provided below is used, or a sequence having at least 85% sequence identity thereto is used. In embodiments, sequences having at least 90%, at least 95%, or at least 98% sequence identity are used.
[0055] DcFLYC1.2 polynucleotide sequence (DmFLYC1.2 codon-optimized polynucleotide sequence):
[0056] The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and mimics that function in a similar manner to naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those that are later modified, such as hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. Amino acid analogs refer to compounds that have the same basic chemical structure as naturally occurring amino acids (i.e., hydrogen, carboxyl group, amino group, and an α-carbon bonded to an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methylsulfonium). Such analogs may have a modified R group (e.g., norleucine) or a modified peptide skeleton, but retain the same basic chemical structure as naturally occurring amino acids. Amino acid mimics refer to chemical compounds that have a different structure from the general chemical structure of amino acids, but function in a similar manner to naturally occurring amino acids. The terms "naturally occurring amino acids" and "non-natural amino acids" refer to amino acid analogs, synthetic amino acids, and amino acid mimics that are not found in nature.
[0057] Amino acids may be referred herein by either their commonly known three-letter codes or the one-letter codes recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides may similarly be referred to by their commonly accepted one-letter codes.
[0058] The term "conservatively modified variant" applies to both amino acid sequences and nucleic acid sequences. For a given nucleic acid sequence, a conservatively modified variant refers to a nucleic acid that codes for the same or essentially the same amino acid sequence, or, if the nucleic acid does not code for an amino acid sequence, for an essentially identical sequence. Due to the degenerate nature of the genetic code, a large number of functionally identical nucleic acids code for any given protein. For example, the codons GCA, GCC, GCG, and GCU all code for the amino acid alanine. Therefore, at all positions where alanine is identified by the codon, the codon can be changed to one of the corresponding codons listed without altering the coded polypeptide. Such nucleic acid mutations are a type of conservatively modified mutation called "silent mutations." All nucleic acid sequences in this specification that code for polypeptides also describe all possible silent mutations of the nucleic acid. Those skilled in the art will recognize that each codon in a nucleic acid (except AUG, usually the sole codon for methionine, and TGG, usually the sole codon for tryptophan) can be modified to produce a functionally identical molecule. Therefore, each silent mutation in the nucleic acid encoding the polypeptide is implied in each described sequence with respect to the expression product, not to the actual probe sequence.
[0059] "Changed" means an increase (or augmentation) or a decrease (or reduction). An increase is any positive change, for example, at least about 5%, 10%, or 20%, or about 25%, 50%, or 75%, or even 100%, 200%, 300%, or more. A decrease is a negative change, for example, a decrease of about 5%, 10%, or 20%, or a decrease of about 25%, 50%, or 75%, or even an increase of 100%, 200%, 300%, or more.
[0060] The terms "comprises" and "comprising" are intended to have the broad meanings assigned to them under U.S. patent law, and can mean "includes," "including," and so on.
[0061] "Contact" is used according to its obvious and ordinary meaning and refers to a process that allows at least two different species (e.g., a chemical compound including biomolecules, reagents, or cells) to react, interact, influence, affect, or become close enough to physically touch. However, it should be understood that the reaction product obtained may be produced from the reaction between added reagents or directly from an intermediate of one or more added reagents, which may be produced in the reaction mixture or under contact conditions. Contact may also include allowing two species to react, interact, or physically touch, and the two species may be recombinant virus particles and cells as described herein. In some embodiments, the two species are an ultrasound contrast agent and cells exposed to ultrasound. In some embodiments, the two species are ultrasound and cells.
[0062] As used herein with respect to genes, the terms “expressed” or “expressed” mean the transcription and / or translation product of that gene. The expression level of a DNA molecule within a cell may be determined based on either the amount of corresponding mRNA present in the cell or the amount of protein encoded by that DNA produced by the cell. The expression level of non-coding nucleic acid molecules (e.g., siRNA) may be detected by standard PCR or Northern blotting methods well known in the art. See, for example, Sambrook et al., 1989 Molecular Cloning: A Laboratory Manual, 18.1–18.88.
[0063] The expression of a transfected gene can occur transiently or stably within a cell. During "transient expression," the transfected gene does not transfer to daughter cells during cell division. Because its expression is limited to the transfected cell, gene expression is lost over time. In contrast, stable expression of a transfected gene can occur when the gene is co-transfected with another gene that confers a selective advantage to the transfected cell. Such a selective advantage may be resistance to a particular toxin presented to the cell. The expression of a transfected gene can further be achieved by transposon-mediated insertion into the host genome. During transposon-mediated insertion, the gene is positioned in a predictable manner between two transposon linker sequences that enable insertion into and subsequent excision of the host genome. Stable expression of a transfected gene can further be achieved by infecting cells with a lentiviral vector, which, after infection, forms part of the cell genome (integrates into the cell genome), thereby resulting in stable gene expression.
[0064] The term “exogenous” (synonymous with “heterogeneous”) refers to molecules, reagents, or substances (e.g., compounds, nucleic acids (polynucleotides), or proteins (polypeptides or peptides)) that originate from or are derived from a source outside a given cell or organism. For example, “exogenous promoter” as used herein is a promoter that does not originate from the source on which it is expressed (e.g., a given cell or organism). For example, “exogenous” or “heterogeneous” polypeptides or polynucleotides as used herein do not originate from the source on which they are expressed (e.g., a given cell, tissue, organ, or organism), but are obtained or derived from a different source and introduced or delivered into a given cell, tissue, organ, or organism by genetic or recombinant technology, and subsequently expressed within that given cell, tissue, organ, or organism. For example, an exogenous promoter may originate from a given organism such as bacteria, plants, or fungi (yeast) and be used in another organism or cell type, such as mammalian cells. Conversely, the term “endogenous” (e.g., “endogenous promoter,” “endogenous protein or polypeptide,” or “endogenous polynucleotide”) refers to a molecule or substance that is native to or originates within a given cell, tissue, organ, or organism. The terms “heterologously expressed” or “exogenously expressed” are used interchangeably herein with respect to the expression of heterologous or exogenous polypeptides in cells.
[0065] A "fragment" means a portion of a polypeptide or nucleic acid molecule. This portion, for example, contains at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the total length of the reference nucleic acid molecule or polypeptide. A fragment may contain 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 nucleotides or amino acids.
[0066] The term "gene" refers to a segment of DNA involved in protein production, including the coding regions (leaders and trailers) between individual coding segments (exons), as well as the regions before and after intervening sequences (introns). Leaders, trailers, and introns contain regulatory elements necessary for gene transcription and translation. Furthermore, a "protein gene product" is the protein expressed from a particular gene.
[0067] "Hybridization" refers to hydrogen bonding between complementary nucleic acid bases, which can be Watson-Crick, Hoogsteen, or reverse Hoogsteen hydrogen bonds. For example, adenine and thymine are complementary nucleic acid bases that pair up through the formation of hydrogen bonds.
[0068] The term “identical” or “identical” percentage refers to two or more nucleic acid or polypeptide sequences that, when measured using the BLAST or BLAST 2.0 sequence comparison algorithm with the default parameters described below, or when measured by manual alignment and visual inspection, are identical or contain identical amino acid residues or nucleotides at a specific percentage (i.e., approximately 60% identity, or 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity across a specific region when compared and aligned for maximum correspondence across a comparison window or specified region). Such sequences are then said to be “substantially identical” or “homologous.” This definition may also refer to or apply to the complementarity of test sequences. This definition also includes sequences with deletions and / or additions, as well as sequences with substitutions. As described below, preferred algorithms can take gaps into account. In one embodiment, identity exists over a region having a length of at least about 25 amino acids or nucleotides, or a region having a length of 50 to 100 amino acids or nucleotides.
[0069] The terms “isolated,” “purified,” or “biologically pure” refer to materials that contain, to varying degrees, components normally associated with them, as they would be found in their natural state. “Isolating” means separation to some extent from the original source or surroundings. “Purifying” means a higher degree of separation than isolation. A “purified” or “biologically pure” protein is sufficiently free of other materials that no impurities substantially affect the protein’s biological properties or cause other harmful consequences. That is, nucleic acids, polypeptides, or peptides are purified if, when produced by recombinant DNA technology, they substantially contain no cellular material, viral material, or culture medium, or if, when chemically synthesized, they substantially contain no chemical precursors or other chemicals. Purity and homogeneity are typically determined using analytical chemistry techniques, such as polyacrylamide gel electrophoresis or high-performance liquid chromatography. The term “purified” can indicate that the nucleic acid or protein produces essentially one band within the electrophoretic gel. For proteins that can undergo modifications, such as phosphorylation or glycosylation, different modifications can result in different isolated proteins that can be purified separately.
[0070] "Isolated polynucleotide" means nucleic acid (e.g., DNA) that does not contain genes adjacent to a particular gene in the naturally occurring genome of the organism from which the nucleic acid molecules described herein originate. Therefore, this term includes, for example, recombinant DNA incorporated into a vector, recombinant DNA incorporated into an autonomously replicating plasmid or virus, or recombinant DNA incorporated into the genomic DNA of a prokaryote or eukaryote, or recombinant DNA existing as a separate molecule independently of other sequences (e.g., cDNA or genome or cDNA fragment produced by PCR or restriction endonuclease digestion). Furthermore, this term includes RNA molecules transcribed from DNA molecules, and recombinant DNA that is part of a hybrid gene encoding additional polypeptide sequences.
[0071] "Isolated polypeptide" means a polypeptide as described herein, which has been isolated from components naturally associated with the polypeptide. Typically, a polypeptide is isolated if it is free from naturally associated proteins and naturally occurring organic molecules, and is at least 50% by weight, at least 55% by weight, or at least 60% by weight. In embodiments, the preparation is at least 75% by weight, at least 90% by weight, or at least 99% by weight of the mechanosensible polypeptide described herein. Isolated polypeptides as described herein can be obtained, for example, by extraction from a natural source, by expression of recombinant nucleic acids encoding such polypeptides, or by chemical synthesis of proteins. Purity can be measured by any suitable method, for example, column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.
[0072] "Mammals" means any warm-blooded animal, including but not limited to non-human primates (such as monkeys, apes, and baboons), humans, cattle, horses, pigs, sheep, goats, mice, rats, dogs, and cats. In one embodiment, the mammal is a human.
[0073] As used herein, “mechanically sensitive,” “mechanically activated,” “mechanoreceptor,” “mechanically transmitted,” “stretch-gated,” “acoustically sensitive,” and other similar technical terms are considered interchangeable and are used to refer to cells, tissues, polypeptides, or other tangible objects that are sensitive to activation or inactivation by acoustic energy such as ultrasound.
[0074] "Modification" means influencing or altering the activity or function of cells, tissues, organs, organisms, or objects by, for example, subjecting them to ultrasonic stimulation. In one embodiment, the activity or function of cells such as insulin-secreting cells or nerve cells is modulated by applying or delivering ultrasound or ultrasound to the cells. In embodiments, modulating cells in an object, for example in the brain or CNS of the object, affects the behavior of the object or its response to a drug, stimulus, situation, effect, or activity. In some embodiments, modulating activity or function may result in an increase (enhancement) or decrease (inhibition or suppression) of cellular activity or function, or the response or responsiveness of the object.
[0075] "Nucleic acid" refers to deoxyribonucleotides or ribonucleotides in either single-stranded or double-stranded form, polymers thereof, or their complements. The term "polynucleotide" refers to a linear sequence of nucleotides. The terms "polynucleotide" and "nucleic acid molecule" are used interchangeably herein. The term "nucleotide" typically refers to a single unit of a polynucleotide, i.e., a monomer. A nucleotide may be a ribonucleotide, a deoxyribonucleotide, or a modified version thereof. Examples of polynucleotides as intended herein include single-stranded and double-stranded DNA, single-stranded and double-stranded RNA (including siRNA), and hybrid molecules having mixtures of single-stranded and double-stranded DNA and RNA. The term also encompasses nucleic acids containing known nucleotide analogs or modified skeletal residues or linkages, which are synthesized, naturally occurring, or not naturally occurring, possess similar binding properties to the reference nucleic acid, and are metabolized in similar ways to the reference nucleotide. Examples of such analogues include, but are not limited to, phosphorothioates, phosphoramides, methylphosphonates, chiral methylphosphonates, and 2-O-methylribonucleotides.
[0076] Nucleic acids are "operably ligated" when they are positioned in a functional relationship with another nucleic acid sequence. For example, pre-sequence or secretion leader DNA is operably ligated to polypeptide DNA when expressed as a preprotein involved in polypeptide secretion; promoters or enhancers are operably ligated to coding sequences when they affect the transcription of the sequence; and ribosome binding sites are operably ligated to coding sequences when they are positioned to facilitate translation. Generally, "operably ligated" means that the DNA sequences to be ligated are in close proximity to each other, and in the case of secretion leaders, they are contiguous and in the read-only stage. Enhancers, however, do not need to be contiguous. Ligation is achieved by ligation at a convenient restriction site. If such a site is not present, synthetic oligonucleotide adapters or linkers are used according to conventional practice.
[0077] The term “obtaining” as in “obtaining a drug” includes synthesizing, inducing, isolating, purchasing, or otherwise acquiring a drug, such as a protein, polynucleotide, or sample.
[0078] "Positioned for expression" means that a polynucleotide (e.g., a DNA molecule) is positioned adjacent to a DNA sequence that directs transcription, and for proteins, it means that the sequence is translated (i.e., facilitates the production of recombinant polypeptides or RNA molecules as described herein).
[0079] The terms "plasmid" or "vector" refer to nucleic acid molecules that encode genes and / or regulatory elements necessary for gene expression. Gene expression from plasmids or vectors can occur in cis or trans configurations. When a gene is expressed in cis configuration, the gene and regulatory elements are encoded by the same plasmid and vector. Trans expression refers to cases where the gene and regulatory elements are encoded by separate plasmids or vectors.
[0080] As used herein, terms such as “prevent,” “prevention,” “prevention,” and “preventive treatment” refer to reducing the likelihood of developing a disorder or condition in an individual who does not have the disorder or condition but is at risk of developing it or is susceptible to developing it.
[0081] "To reduce" means a negative change of at least 5%, 10%, 25%, 50%, 75%, or 100%.
[0082] "Reference" or "control" refers to a standard state. For example, it could be an untreated cell, tissue, or organ used as a reference.
[0083] The terms “protein,” “peptide,” and “polypeptide” are used interchangeably to refer to an amino acid polymer, or a set of two or more interacting or bound amino acid polymers. This term applies to amino acid polymers in which one or more amino acid residues are artificial chemical mimics of corresponding naturally occurring amino acids, as well as to naturally occurring and non-naturally occurring amino acid polymers. For certain polypeptides described herein (e.g., MscS, MscL, MscK, MscL G22S, MscS-like, MscMJ, MscMJLR, Msc-like 3, MscSfam), the named polypeptide includes either the naturally occurring form of the polypeptide or any of the variants, isoforms, or homologs that maintain the mechanesensory activity of the polypeptide (e.g., within at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of the activity compared to the natural polypeptide). In some embodiments, the variant or homolog has at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity over the entire polypeptide sequence or a portion thereof (e.g., a segment of 50, 100, 150, or 200 consecutive amino acids) compared to the naturally occurring form. In other embodiments, the polypeptide is a polypeptide identified by its Genbank accession number.
[0084] The ranges provided herein are understood to be abbreviations for all values within that range. For example, the range 1 to 50 is understood to include any number, combination of numbers, or subrange from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50.
[0085] The term "recombinant," when used in reference to, for example, cells, nucleic acids, proteins, or vectors, indicates that the cells, nucleic acids, proteins, or vectors have been modified by the introduction of heterologous nucleic acids or proteins or by alteration of native nucleic acids or proteins, or that the cells originate from such modified cells. For example, recombinant cells express genes not found in the cell's native (non-recombinant) form, or express native genes that are otherwise abnormally expressed, underexpressed, or not expressed at all. Transgenic cells and plants typically express heterologous genes or coding sequences as a result of recombination methods.
[0086] The terms “sonogenetics,” “sonogenetic,” “sonogenics,” or “sonogenic” refer to non-invasive approaches, methods, or techniques for manipulating, controlling, or modulating the activity or function of cells or cell types, such as neurons (e.g., motor neurons), that express heterogeneous or exogenous mechanosensitive (also called mechanosensitive) channels that respond to ultrasound, such as low-intensity ultrasound. Cellular activity, such as neuronal activity, can be controlled or modulated by exposing target cells, such as neurons or neuronal cell types, to ultrasound (low-intensity ultrasound) by causing them to express heterogeneous or exogenous mechanosensitive channels, thereby enabling them to respond to ultrasound or ultrasound pulses. In one embodiment, the cell type is located in the mammalian brain. Target cells expressing such heterogeneous or exogenous mechanosensitive channels are specific cells that make those cells sensitive to mechanical deformations produced by non-invasive ultrasound. In one embodiment, the cells are neurons within a region of the brain or within the spinal cord (central nervous system, CNS). In one embodiment, the cells are located within the peripheral nervous system (PNS). In one embodiment, the brain region is the hypothalamus. In one embodiment, ultrasound is delivered to or applied to the hypothalamus using an external transducer. In one embodiment, the transducer is non-invasively placed on the head of an awake mammalian subject. In one embodiment, the transducer is a PZT-based transducer. In one embodiment, the cells are neurons within the spinal cord.
[0087] As used herein, the term “subject” refers to vertebrates, such as mammals, such as dogs, cats, rodents, horses, cattle, rabbits, goats, non-human primates, or humans. In one embodiment, the subject may be a human individual or a patient.
[0088] "Substantially identical" means a polypeptide or nucleic acid molecule that exhibits at least 50% identity with respect to a reference amino acid sequence (e.g., any one of the amino acid sequences described herein) or a nucleic acid sequence (e.g., any one of the nucleic acid sequences described herein). In embodiments, such a sequence is at least 60%, or at least 80% or 85%, or at least 90%, 95%, or even 99% identical to the sequence used for comparison at the amino acid level or nucleic acid level.
[0089] Sequence identity is typically measured using sequence analysis software (e.g., the Sequence Analysis Software Package, BLAST, BESTFIT, GAP, or PILEUP / PRETTYBOX programs from the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705). Such software matches identical or similar sequences by assigning degrees of homology to various substitutions, deletions, and / or other modifications. Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine, lysine, arginine; and phenylalanine, tyrosine. An exemplary approach to determining the degree of identity may use the BLAST program, e -3 ~e -100 The probability scores indicate closely related sequences.
[0090] "Transformed cells" means cells into which polynucleotide molecules (or their ancestors) encoding the polypeptides described herein have been introduced by recombinant DNA technology.
[0091] As used herein, the terms “to treat,” “to treat,” and “treatment” refer to reducing, alleviating, decreasing, improving, or eliminating a disease, disorder, pathology, or condition and / or symptoms associated therewith. It should be understood that treating a disease, disorder, or condition does not require the complete elimination of the disease, disorder, pathology, condition, or symptoms associated therewith, though this is not excluded.
[0092] "Transformed cells" means cells into which polynucleotide molecules (or their ancestors) encoding the polypeptides described herein have been introduced by recombinant DNA technology.
[0093] The terms “transfection,” “transfer,” “transfecting,” or “transferring” can be used interchangeably and are defined as the process of introducing a nucleic acid molecule or protein into a cell. Nucleic acids are introduced into cells using non-viral or virus-based methods. Nucleic acid molecules may be complete proteins or gene sequences encoding their functional parts. Non-viral methods of transfection include any suitable transfection method that does not use viral DNA or viral particles as a delivery system for introducing nucleic acid molecules into cells. Exemplary non-viral transfection methods include calcium phosphate transfection, liposome transfection, nuclear fusion, sonoporation, heat shock transfection, magnetofection, and electroporation. In some embodiments, nucleic acid molecules are introduced into cells using electroporation in accordance with standard procedures well known in the art. For virus-based methods of transfection, any useful viral vector may be used in the methods described herein. Examples of viral vectors include, but are not limited to, retroviruses, adenoviruses, lentiviruses, and adeno-associated virus vectors. In some embodiments, nucleic acid molecules are introduced into cells using retroviral vectors in accordance with standard procedures well known in the art. The term “transfection” also refers to the introduction of proteins into cells from an external environment. Typically, protein transfection or substitution depends on the binding of a peptide or protein capable of crossing the cell membrane to the protein of interest. See, for example, Ford et al. (2001) Gene Therapy 8:1-4 and Prochiantz (2007) Nat. Methods 4:119-20.
[0094] As used herein, terms such as “to treat,” “to treat,” and “treatment” refer to reducing or improving a disorder and / or its associated symptoms. It will be understood, though not excluded, that treating a disorder or condition does not require the complete elimination of the disorder, condition, or its associated symptoms.
[0095] An “effective dose” is the amount sufficient to achieve the stated purpose (e.g., to achieve the effect it is administered, to treat a disease, to reduce enzyme activity, to reduce one or more symptoms of a disease or condition, or to reduce intracellular viral replication). An example of an “effective dose” is an amount sufficient to contribute to the treatment, prevention, or reduction of one or more symptoms of a disease, which may also be called a “therapeutic effective dose.” “Reduction” (and the grammatical equivalent of this phrase) of one or more symptoms means a reduction in the severity or frequency of a symptom, or the elimination of a symptom. The “preventive effective dose” of a drug is the amount of the drug, when administered to a subject, that prevents or delays the onset (or recurrence) of the intended preventive effect, e.g., the onset (or recurrence) of an injury, disease, condition or state, or reduces the likelihood of the onset (or recurrence) of an injury, disease, condition or state, or its symptoms. Complete preventive effect does not necessarily result from a single dose, but may only occur after a series of doses. A preventive effective dose may be administered in one or more doses. As used herein, “activity reduction” refers to the amount of antagonist required to reduce the activity of an enzyme or protein (e.g., Tat, Rev) compared to the absence of the antagonist. As used herein, “functional disruption” refers to the amount of antagonist required to disrupt the function of an enzyme or protein compared to the absence of the antagonist. The exact amount will vary depending on the purpose of the treatment and can be determined by those skilled in the art using known techniques (see, for example, Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992), Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999), Pickar, Dosage Calculations (1999), and Remington: The Science and Practice of Pharmacy, 20th Edition, 2003, Gennaro, Ed., Lippincott, Williams & Wilkin).
[0096] "Patient," "Subject," or "Subject in need thereof" refers to a living organism or individual suffering from, afflicted with, having, being at risk of, or susceptible to, a disease, condition, disorder, or state that can be treated by using the products, compositions, and methods provided herein. The term does not necessarily imply that the subject has been diagnosed with a specific disease, and typically refers to an individual under medical supervision. Non-limiting examples include humans, other mammals, cattle, rats, mice, dogs, monkeys, goats, sheep, deer, and other non-mammalian animals. In some embodiments, the patient or subject is human.
[0097] The terms “ultrasonic wave,” “acoustic energy,” “sound wave,” or “ultrasound” are used interchangeably herein to refer to interference in a material, corresponding to the mechanical transfer or mechanical transduction of energy through the material. In various embodiments, the interference is the vibration of the material's constituent elements. In some embodiments, the material is a certain volume of liquid, cells, cell membranes, tissue, or organ.
[0098] As used herein, the term “or” is understood to be inclusive unless otherwise specifically stated or evident from the context. As used herein, the terms “a,” “an,” and “the” are understood to be singular or plural unless otherwise specifically stated or evident from the context.
[0099] Where used herein, the term “approximately” is understood to mean within the normal tolerance range in the art, e.g., within two standard deviations of the mean, unless otherwise specified or made clear from the context. “Approximately” may be understood to mean within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the stated value. Unless otherwise made clear from the context, all numerical values provided herein are modified by the term “approximately.”
[0100] Any description of a variable in this specification that lists chemical groups in any definition includes the definition of that variable as any single group or as a combination of the listed groups. Any description of embodiments of a variable or aspect in this specification includes that embodiment as any single embodiment described herein, or in combination with any other embodiment or part thereof.
[0101] Any composition or method and its embodiments provided herein may be combined with one or more other compositions, methods, and their embodiments provided herein. [Brief explanation of the drawing]
[0102] [Figure 1A]Figures 1A–1D show images, scanning electron micrographs, plots, and bar graphs related to the identification of presumed mechanesensory channels in the sensory hairs of Venus flytrap. Figure 1A shows representative images of a Venus flytrap clone grown in soil (left), a Venus flytrap leaf (center), and a single sensory hair (right). The black arrow in the center image indicates the presence of a sensory hair on the leaf. Figure 1B shows a scanning electron micrograph of a sensory hair. Cells of the liver (L), depression zone (In), and petiole (P) are shown. Digestive glands are also visible on the floor of the lobe. Figure 1C presents a plot showing the enrichment ratio of protein-coding genes with a length of more than 100 amino acids (black circles) in the sensory hair compared to the trap. FLYC1, FLYC2, and OSCA are labeled "CPM" (i.e., counts per million mapped sequencing reads). Figure 1D shows bar graphs illustrating the mean fragments (FPKMs) per kilobase of transcripts per million mapped reads for FLYC1, FLYC2, and OSCA in trap and sensory hairs. Gray dots of the same shade indicate paired biological replications. **FDR < 0.005. [Figure 1B] Refer to the explanation in Figure 1A. [Figure 1C] Refer to the explanation in Figure 1A. [Figure 1D] Refer to the explanation in Figure 1A. [Figure 2A]Figures 2A to 2E present phylogenetic trees and polypeptide topology maps relating to the molecular phylogenetic relationships of FLYCATCHER and OSCA proteins. Figure 2A presents a phylogenetic tree showing a maximum likelihood phylogenetic analysis illustrating the relationships between the conserved MscS domain of Escherichia coli MscS protein, Arabidopsis thaliana MSL proteins (MSL1 to MSL10), and FLYCATCHER proteins of Dionaea muscipula (DmFLYC1 and DmFLYC2) and Drosera capensis (DcFLYC1.1 and DcFLYC1.2). Figures 2B and 2C show polypeptide topology maps illustrating the predicted topologies of DmFLYC1 (Figure 2B) and DmFLYC2 (Figure 2C) proteins. Figure 2D is a phylogenetic tree presenting a maximum likelihood phylogenetic analysis showing the relationship between Arabidopsis thaliana OSCA family proteins and Venus flytrap DmOSCA. Figure 2E is a polypeptide topology map showing the predicted topology of the DmOSCA protein. Figures 2A and 2D show more than 50 bootstrap values, indicating scale and site-specific substitutions. In Figures 2B, 2C, and 2E, amino acid residues conserved in Arabidopsis MSL10, MSL5, and OSCA1.5, respectively, are shown as dark circles, while residues with similar identity are shown as lighter circles. Predicted pore domains for each protein are enclosed by black lines. [Figure 2B] Refer to the explanation in Figure 2A. [Figure 2C] Refer to the explanation in Figure 2A. [Figure 2D] Refer to the explanation in Figure 2A. [Figure 2E] Refer to the explanation in Figure 2A. [Figure 3A]Figures 3A to 3E are images demonstrating the localization of FLYC1 mRNA in Venus flytrap sensory hairs. Figure 3A shows a toluidine blue stained longitudinal section across the base of a sensory hair. Elongated sensory cells are visible in the depression zone (arrow). Figure 3B presents a maximum projection image across the longitudinal section after fluorescence in situ hybridization. (Top) FLYC1 transcript and DAPI at low (left) and high (right) magnification in the depression zone. FLYC1 transcript sites were localized in sensory cells. (Bottom) No signal was observed when a FLYC1 sense probe was used. High background fluorescence was observed in all channels. Figure 3C shows a toluidine blue stained cross section across the depression zone. The cells forming the outer ring are presumed to be mechanosensors. Figure 3D presents a maximum projection image across the cross section after fluorescence in situ hybridization. FLYC1 transcripts (red) at low (left) and high (right) magnification. FLYC1 transcript sites were mainly localized in sensory cells in the depression zone. Figure 3E presents a maximum projection image across a cross-section of a sensory hair lever. No transcripts were observed. Scale bar, μm. [Figure 3B] Refer to the explanation in Figure 3A. [Figure 3C] Refer to the explanation in Figure 3A. [Figure 3D] Refer to the explanation in Figure 3A. [Figure 3E] Refer to the explanation in Figure 3A. [Figure 4A]Figures 4A–4D are a collection of plots, schematics, and bar graphs demonstrating that FLYC1 induces a stretch activation current. Figure 4A provides a schematic diagram of the patch-clamp method and a plot showing a representative trace of the stretch activation current recorded from FLYC1-expressing HEK-P1KO cells in a cell-attached patch-clamp configuration at a membrane potential of -80mV. Stimulus traces are shown above the current trace. Left: Current in response to graded negative pressure steps from 0–100mmHg (Δ10mmHg). Right: Current in response to a single pulse of -70mmHg pressure. Figure 4B is a bar graph showing quantification of the maximum current response from cells transfected with mock (N=7), mouse PIEZO1 (N=5), or FLYC1 plasmid (N=10). p=0.0251 (mock vs. PIEZO1), p=0.0070 (mock vs. FLYC1), Dunn's multiple comparison test. Figure 4C (left) presents a plot showing representative single-channel traces in response to stretching at the indicated membrane potential. Figure 4C (right) presents a plot showing the mean IV relationship of stretch-activated single-channel currents from FLYC1-transfected cells. Figure 4D (left) presents a plot showing representative stretch-activated single-channel currents recorded from excised inside-out patch configurations in asymmetric NaCl solution at the indicated membrane potential. Figure 4D (right) presents a plot showing the mean IV of stretch-activated single-channel currents in asymmetric NaCl solution (Erev: -30.0 ± 1.4 mV (N=7)). [Figure 4B] See the explanation in Figure 4A. [Figure 4C] See the explanation in Figure 4A. [Figure 4D] See the explanation in Figure 4A. [Figure 5A]Figures 5A–5E are images and bar graphs demonstrating the localization of DcFLYC1.1 and DcFLYC1.2 to the touch-sensing structures of the genus Drosera. Figure 5A is an image of a leaf of Drosera rotundifolia showing tactile projections with mucous secretions. Figure 5B is an image of tactile bristles bending in response to insect (housefly) contact. The arrowhead shows an example of tactile bristles bending inward. Figure 5C is a bar graph showing the relative expression of DcFLYC1.1 and DcFLYC1.2 in Drosera rotundifolia tactile bristles compared to leaves without tactile bristles, as determined by qRT-PCR. ** p<0.005, moderate t-test, results from four biological replicas of each tissue type. Figure 5D presents an image of a toluidine blue-stained longitudinal section of the head and upper neck of Drosera rotundifolia tactile bristles. The head consists of xylem (X), endodermis (E), and secretory cells (S). Figure 5E presents maximum projection images at low (left) and high magnification (right) showing the aggregate localization of DcFLYC1.1 and DcFLYC1.2 mRNA to the lateral secretory cells of the palpebrae head (top). Arrows indicate exemplary secretory cells with DcFLYC points. No signal was observed on the background in the lobe (bottom). In Figures 5A, 5B, 5D, and 5E, the scale bar represents μm. [Figure 5B] Refer to the explanation in Figure 5A. [Figure 5C] Refer to the explanation in Figure 5A. [Figure 5D] Refer to the explanation in Figure 5A. [Figure 5E] Refer to the explanation in Figure 5A. [Figure 6A]Figures 6A and 6B are schematic diagrams presenting models of contact-induced movement in carnivorous sundew plants. Figure 6A presents a schematic model of the Venus flytrap. While we do not wish to be bound by theory, mechanical stimulation of the sensory hairs by a prey animal causes the sensory cells in the depression zone to bend (1), leading to the activation of mechanically induced mechanosensible (MS) channels and chloride leaching (2). This induces an action potential that propagates from the base of the sensory cells to the petiole cells via plasmodesmata (3). The propagation of the action potential through the leaf lobes leads to trap closure. Figure 6B shows a schematic model of the sundew tactile hairs. While we do not wish to be bound by theory, the pulling of the mucus may lead to the activation of DcFLYC1.1 and DcFLYC1.2 proteins in the outer cell layer of the tactile head, potentially causing downward propagation of the action potential through the tactile stem. [Figure 6B] See the explanation in Figure 6A. [Figure 7A] Figures 7A and 7B are images and diagrams relating to the Venus flytrap clonal propagation system. Figure 7A is an image showing an example of clonal Venus flytraps growing in tissue culture (10 cm plate) using a method adapted from Jang and Park. See Jang, GW, Kim, KS, & Park, RD (2003) “Micropropagation of Venus fly trap by shoot culture” Plant Cell Tissue and Organ Culture, 72(1), 95-98. Figure 7B is a diagram illustrating the propagation method. Rosettes were isolated by dividing the rhizome. The plants were then transferred to fresh sterile growth medium for further propagation during culture, or transferred to soil and “hardened” for at least 2-3 months before the experiment. [Figure 7B] Refer to the explanation in Figure 7A. [Figure 8A]Figures 8A and 8B present images showing autofluorescence and EF1α transcript expression in Venus flytraps. Figure 8A presents images of untreated Venus flytrap sensory hairs in different channels to show autofluorescence from the plant cuticle. The images were taken in the same settings as the tissue subjected to in-situ hybridization. Figure 8B shows longitudinal sections of sensory hairs and traps with smFISH for housekeeping genes EF1α and FLYC1 and DAPI. White arrows indicate examples of EF1α expression in various cells throughout the tissue. Scale bar, μm. [Figure 8B] See the explanation in Figure 8A. [Figure 9A] Figures 9A and 9B present images showing the expression of FLYC2 and DmOSCA transcripts in sensory hairs. (Figure 9A) Maximum projection across longitudinal sections after fluorescence in situ hybridization of DmFLYC2 transcript and (Figure 9B) DmOSCA transcript at low (left) and high (center and right) resolutions. No DmFLYC2 transcript was observed, while OSCA was observed mainly in sensory cells. Scale bar, μm. [Figure 9B] See the explanation in Figure 9A. [Figure 10] This bar graph shows the functionality of DmFLYC2 and DmOSCA. Macroscopic extension activation currents were recorded from HEK P1-KO cells transfected with plasmids containing polynucleotides encoding each of the polypeptides identified along the X-axis: mock (N=7), MmPiezo1 (N=5), AtMSL10 (N=9), DmFLYC1 (N=10), DmFLCY2 (N=10), AtOSCA1.5 (N=4), and DmOSCA (N=12). [Figure 11] Plots and schematic diagrams are shown. Figure 11 presents a plot showing chloride permeability in DmFLYC1. Mean IV (N=5) of DmFLYC1 extension activation current recorded in a cell adhesion patch clamp configuration. The recording pipette was composed of 100 mM calcium gluconate. The schematic diagram shows the patch clamp technique for recording the extension activation current. [Figure 12A] Figures 12A to 12D present plots of sequence alignment, protein structure images, and the sequence of the predicted pore-forming helix in FLYC1, which is compatible with the MscS-like channel structure. Figure 12A shows the sequence alignment of MSL10 and MscS with the predicted pore helix of the Venus flytrap FLYC1 and Drosera DcFLYC1.1 and DcFLYC1.2 proteins. Nonpolar and polar residues are shown in light gray, and ionizable residues are shown in dark gray. Glycine, which is predicted to be localized in the central bend of the helix, is shown in a gray box. The sequence presented in Figure 12A is as follows: FLYC1(D.muscipula):ATTKLIVLLSSQLVVAAFIFGNTCKTIFEAIIFVFVMHP(Sequence ID 1). FLYC1.1(D.capensis):MTTKVLLFFSSQLLVAVFVFGNTCKTIFEAIIFVFVMHP(SEQ ID NO: 2). FLYC1.2(D.capensis):MTTKVLLFFTSQLLVAVFVFGNTCKTIFEAIIFVFVMHP(SEQ ID NO: 3). McsS(E.coli):QTASVIAVLGAAGLAVGLALQGSLSNLAAGVLLVMFRPF(SEQ ID NO: 4). Figure 12B is an image presenting the modeled heptameric structure. The Venus flytrap FLYC1 sequence was screwed onto the internal helix of the heptameric MscS in a closed conformation (PDB 2OAU), and minimized using the rosette energy function while imposing C7 symmetry. Predicted intersubunit hydrogen bonds between serines in the pore segments are shown, while the phenylalanine ring (F572) causes pore contraction. The central pore-forming helix TM6a and the amphiphilic helix TM6b are shown for one pore segment. Figure 12C is a cross-sectional image across the protein surface colored by electrostatic potential, showing the uncharged (light gray) pores and the positively charged (darker gray) areas above and below the pores. Figure 12D is a plot showing the mean IV of the extension-activated single-channel current from FLYC1(N=7) and FLYC1(K579E)(N=4) in asymmetric NaCl solution. The FLYC1 data are similar to those in Figure 3D. [Figure 12B] Refer to the explanation in Figure 12A. [Figure 12C] Refer to the explanation in Figure 12A. [Figure 12D] Refer to the explanation in Figure 12A. [Figure 13A] Figures 13A and 13B are scanning electron microscope images showing variations in the tentacles of Drosera rotundifolia. Figure 13A is a scanning electron microscope (SEM) image showing mucosal tentacles of different lengths on the leaf blade of Drosera rotundifolia. Asterisks (*) indicate staging needles. The tentacles become longer towards the leaf margin. Figure 13B presents a composite image of three SEM microscope images showing bent tentacles around a fly, Drosophila melanogaster. Scale bar, 200 μm. [Figure 13B] Refer to the explanation in Figure 13A. [Figure 14] This image shows the unique cellular morphology of *Drosera rotundifolia* sensory / excretory cells by presenting a toluidine blue-stained longitudinal section across the head of the tentacle hairs. E: Endothelial-like cells; S: Outer two layers of secretory cells. The arrows indicate the unique cell wall buttresses of a single outer secretory cell, around which membrane cracks (crenellations) occur. [Figure 15] A graph demonstrating the functionality of Drosera FLYC is presented. Macroscopic extension activation currents recorded from HEKP1-KO cells transfected with mock (N=7), DmFLYC1 (N=10), DcFLCY1.1 (N=7), DcFLYC1.2 (N=10), and DcFLYC1.1 / 1.2 (N=11) plasmids. [Figure 16A] Figures 16A and 16B present images and plots demonstrating that Venus flytrap leaves respond to ultrasonic stimulation. Figure 16A presents images showing Venus flytrap leaves open (top) and closed (bottom) after ultrasonic stimulation. Figure 16B shows a plot indicating the number of 100-millisecond pulses required to close the trap at different ultrasonic intensities. For each condition, n > 30. Mean and standard deviation are shown. [Figure 16B] Refer to the explanation in Figure 16A. [Figure 17A] Figures 17A and 17B present plots demonstrating that FLYC1 suppresses INS1 activity upon application of ultrasound. The plots show the ratio of the change in GCaMP fluorescence relative to baseline in INS1 control (Figure 17A) and INS1-FLYC1 cells (Figure 17B) (y-axis has units of delta F / F). 100 millisecond pulses of ultrasound are represented by the gray vertical bands. n > 17. The x-axis is labeled "frames" in units of 0.1 seconds, and the y-axis is labeled "delta F / F". [Figure 17B] Refer to the explanation in Figure 17A. [Figure 18A] Figures 18A and 18B provide graphs showing that FLYC1 suppresses INS1 activity during ultrasound. The graph in Figure 18A demonstrates that INS1 cells exhibit a dose-dependent response to KCl in the FLIPR assay. The graph in Figure 18B shows that FLYC1 expression suppresses the INS1 response to KCl during ultrasound stimulation. Each figure is based on a Bonferroni-corrected t-test with n=12 wells and p<0.05. [Figure 18B] See the explanation in Figure 18A. [Figure 19] We present patch-clamp electrophysiological traces resulting from monitoring of sonosilencing channels. The traces provide examples of excitatory HEK cells expressing FLYC1, stimulated with ultrasound stimuli of different durations from a 6.91 MHz transducer. [Figure 20] Figures 20A and 20B show dot plots demonstrating that FLYC1 suppresses ultrasound-induced hsTRPA1 calcium events. The percentage change in GCaMP fluorescence relative to baseline in hsTRPA1+dTom control or hsTRPA1+FLYC1-expressing HEK cells upon ultrasound stimulation (Figure 20A) or exposure to an AITC chemical agonist (30 μM concentration) (Figure 20B) is shown. For each condition, n>60. ** indicates p<0.01 by logistic regression. [Figure 21A]Figures 21A and 21B show representative traces and plots demonstrating that the R334E variant exhibits different activation dynamics. Figure 21A shows exemplary traces of the extending activation current from HEK-P1KO cells expressing wild-type (WT) (upper trace) and R334E (lower trace) in a cell adhesion configuration at a membrane potential of -80 mV in response to a pipette pressure of -70 mmHg. Figure 21B (left plot) shows the current time and inactivation time (right plot) for the cells described in Figure 21A. n=6. ** indicates p<0.01. Dunn's multiple comparison test. [Figure 21B] Refer to the explanation in Figure 21A. [Modes for carrying out the invention]
[0103] Detailed description of the embodiment Products and compositions characterized by mechanesensory polypeptides and polynucleotides, methods for expressing such polypeptides and polynucleotides in a target cell type, and methods for inducing the activation of mechanesensory polypeptides in nerve cells (e.g., neurons) and other cell types using ultrasound are provided and characterized herein.
[0104] The embodiments and models described herein are at least in part based on the discovery that certain plant-derived proteins, such as mechanosensory proteins, confer susceptibility to ultrasound when transfected or introduced into target cells and expressed as heterologous proteins on the surface of target cells. The examples provided and described herein demonstrate that such mechanosensory proteins are susceptible to ultrasound. While we do not wish to be bound by theory, ultrasound may cause mechanical deflection in a focal zone that leads to activation of the expressed mechanosensory protein. In the embodiments described and illustrated herein, mechanosensory proteins can be used non-invasively to control cells.
[0105] In particular, as described and illustrated herein, the Venus flytrap protein FLYCATCHER1 (FLYC1) was identified as a polypeptide (protein) capable of inducing chloride-permeable extension activation and / or ultrasound-activated currents in naive cells transfected or transduced with polynucleotides encoding the polypeptide (protein). As described and demonstrated herein, FLYC1 is a chloride-selective inhibitory mechanosensible channel protein in mammalian cells. FLYC1 is expressed in excitable HEK cells and spontaneously active insulinoma cells (INS-1), and the protein was able to inhibit activity in an ultrasound-dependent manner in both types of cell lines. While we do not wish to be bound by theory, we have determined that the FLYC1 polypeptide is a mechanosensible ion channel that may enable the Venus flytrap to sense contact. The products, compositions, and methods described herein enable precise targeting of cell inhibition and allow for the inhibition or suppression of cell activity upon ultrasound stimulation.
[0106] As described and illustrated herein, members of the FLYC and OSCA families of ion channels were identified as candidate mechanosensors for rapid touch in carnivorous plants. Both ion channel families were shown to be enriched in the sensory trigger hairs of Venus flytraps. Among these, the FLYC1 gene was identified as a primary candidate because its mRNA is highly expressed / enriched in mechanesensory cells that presumably initiate the transduction of touch-inducible signals. The encoded polypeptide, FLYC1, formed a mechanically activated ion channel with properties that would facilitate the generation of action potentials in sensory cells. In addition, FLYC gene expression was remarkably conserved in two morphologically distinct touch-sensitive structures from different genera of the Droseraceae family.
[0107] As described and demonstrated in the examples herein, robust macroscopic currents and single-channel extension activation currents were detected in FLYC1-expressing cells of a mammalian cell expression system, identifying residues crucial to channel characterization and supporting the finding that FLYC1 forms a mechanosensitive ion channel. While not intended to be theoretical, chloride-permeable channels like FLYC1 may contribute to membrane depolarization in plant cells. This is consistent with previous findings that increasing extracellular chloride ion concentrations reduce or halt the electrical response of Venus flytrap sensory cells to mechanical stimuli. FLYC1-mediated depolarization, possibly in combination with FLYC2 and OSCA (mechanosensitive calcium-permeable ion channels), may initiate action potentials that propagate to leaves via plasmodesmata clustered basally on the sensory cell side, leading to trap closure (Figure 6A). A similar sequence of events would occur in sundew tufts: contact between a prey and a tuft propagates via plasmodesmata along the mechanosensory head of the tuft and the outer cell layer of the stem, resulting in a DcFLYC-induced action potential that can induce tuft bending (Figure 6B). In one embodiment, in plant cells, FLYC1 is likely to be a chloride-selective excitatory mechanosensible channel protein in plant cells. The findings described and illustrated herein are consistent with the identification of FLYC1 as a true sensor of contact. In various embodiments, the FLYC1 polypeptide may be used to modulate its activity in cells when expressed as a heterologous polypeptide within the cell.
[0108] In various embodiments, the heterologous mechanesensory proteins described herein can be used to make neurons, cardiac muscle, bladder tissue, T cells, or beta cells respond to ultrasound. In some embodiments, mechanesensory proteins can be used to make cells sensitive to ultrasound that is sensitive to rapid changes in cation (e.g., calcium, potassium, sodium) or anion (e.g., chloride, fluoride, bromide, or iodide) concentrations. Cellular function can be altered in vivo, in vitro, or ex vivo using mechanesensory proteins. In addition, mechanesensory proteins can be used to alter the cellular function of cells expressing these proteins during cell culture.
[0109] Accordingly, polynucleotides encoding mechanesensible polypeptides, expression vectors containing such polynucleotides, cells expressing heterologous mechanesensible polypeptides, cells expressing heterologous recombinant mechanesensible polypeptides, and methods for stimulating such cells with ultrasound are provided and described.
[0110] Ultrasound Ultrasound is well-suited for stimulating neuronal populations because it can be easily focused through intact, thin bone and deep tissue to a volume of just a few cubic millimeters (GT. Clement and K. Hyynynen, Phys Med Biol 47(8), 1219 (2002)) (K. Hyynynen and FA. Jolesz, Ultrasound Med Biol 24(2), 275 (1998)). The non-invasive nature of ultrasound stimulation is particularly important for manipulating vertebrate neurons, including human neurons, as it eliminates the need for invasive techniques such as surgery to insert optical fibers (which are required for some current optogenetic methods). Furthermore, the small focal volume of ultrasound is often compared to light scattered by multiple layers of brain tissue (SIAl-Juboori et al., PLoS ONE 8(7), e67626 (2013)). Furthermore, ultrasound has long been used to manipulate the deep nerve structure of the human hand and alleviate chronic pain (WDO'Brien, Jr., Prog Biophys Mol Biol 93(1-3), 212 (2007); LRGavrilov et al., Prog Brain Res 43, 279 (1976)). As described herein, novel non-invasive compositions for the heterologous expression of mechanesensory polypeptides in cells are provided, and methods are provided for stimulating or modulating the activity or function of cells expressing heterologous mechanesensory polypeptides using low-intensity ultrasound stimulation. In one embodiment, the cells expressing heterologous mechanesensory polypeptides are nerve cells, and the method involves neuromodulation by the non-invasive use of ultrasound stimulation, particularly low-intensity ultrasound.
[0111] Cells and cell compositions containing recombinant mechanesensory polypeptides Cells are provided that contain heterologous nucleic acid molecules encoding mechanesensible polypeptides (e.g., FLYC1). Such mechanesensible polypeptides are heterologously or exogenously expressed in the cell type of interest. In one embodiment, the cell type of interest expresses the heterologous mechanesensible polypeptide described herein and is sensitive to rapid changes in the concentration of anions (e.g., chloride, bromide, fluoride, or iodide) or cations (e.g., calcium, potassium, sodium) related to the mechanesensory modulation or inhibition of cell activity by ultrasound. In one embodiment, the cell type is a cardiomyocyte containing a mechanesensible polynucleotide under the control of a promoter suitable for expression in cardiac cells (e.g., the NCX1 promoter). In one embodiment, the cell type is a muscle cell containing a mechanesensible polynucleotide under the control of a promoter suitable for expression in muscle cells, e.g., the myoD promoter. In another embodiment, the cell type is an insulin-secreting cell (e.g., a beta(β) islet cell) containing a mechanesensible polynucleotide under the control of a promoter suitable for expression in insulin-secreting cells, e.g., the Pdx1 promoter. In another embodiment, the cell type is an adipocyte containing a mechanosensory polynucleotide under the control of a promoter suitable for expression in adipocytes (e.g., iaP2). In another embodiment, the cell type is a neuronal cell type (neuron) containing a mechanosensory polynucleotide under the control of a promoter suitable for expression in nerve cells. In one embodiment, as a non-limiting example, the nerve cell is a neuron of the central or peripheral nervous system, a neuron of the brain or spinal cord, a motor neuron, a sensory neuron, an interneuron, or an agouti-associated protein expression-positive (AGRP-) +ve) may be neurons. As a non-limiting example, the nestin or Tuj1 promoter is generally suitable for the expression of mechanesensory polynucleotides in neurons, the H2b promoter is suitable for the expression of mechanesensory polynucleotides in motor neurons, the Islet 1 promoter is suitable for the expression of mechanesensory polynucleotides in interneurons, and the OMP promoter, T1R, T2R promoter, rhodopsin promoter, or Trp channel promoter is suitable for the expression of mechanesensory polynucleotides in sensory neurons. In some embodiments, the cells are plant cells. In some embodiments, the cells may be immune system cells, such as T cells, B cells, monocytes, macrophages, or natural killer (NK) cells. Such cells may be in vitro, ex vivo, or in vivo cells. In certain embodiments, the cells express a mechanesensory polypeptide that is sensitive to ultrasound. In certain embodiments, the mechanesensible polypeptide is the DmFLYC1, DmFLYC2, DmOSCA, DcFLYC1.1, or DcFLYC1.2 polypeptide, or its functional part, isoform, ortholog, or homolog. In other embodiments, the mechanesensible polypeptide, such as the DmFLYC1, DmFLYC2, DmOSCA, DcFLYC1.1, or DcFLYC1.2 polypeptide, or its functional part, isoform, ortholog, or homolog, or a polynucleotide encoding the mechanesensible polypeptide, is codon-optimized for expression in mammalian or plant cells. In other embodiments, the mechanesensible polypeptide, such as the DmFLYC1, DmFLYC2, DmOSCA, DcFLYC1.1, or DcFLYC1.2, or its functional part, isoform, ortholog, or homolog, or a polynucleotide encoding the mechanesensible polypeptide, is codon-optimized for expression in mammalian or human cells.
[0112] Recombinant mechanesensory polypeptide expression In one approach, target cells (e.g., neurons such as motor neurons, sensory neurons, or neurons of the central or peripheral nervous system, nerve cell lines, or plant cells) are genetically or recombinantly engineered to express heterologous mechanesensory polynucleotides, which, upon expression, make the cells responsive to ultrasonic stimulation. Ultrasonic stimulation of such cells induces the influx or efflux of cations or anions. Molecular techniques involved in genetically or recombinantly engineering cells to express heterologous polypeptides are well known to those skilled in the art and are routinely practiced.
[0113] Mechanosensory polypeptides may be constitutively expressed, or their expression may be regulated by an inducible promoter or other regulatory mechanism under conditions requiring highly controlled regulation or timing of mechanosensory polypeptide expression. For example, heterologous DNA encoding the mechanosensory polypeptide gene to be expressed is inserted into one or more pre-selected DNA sequences. This can be achieved by homologous recombination or by viral integration into the host cell genome. The desired gene sequence can also be integrated into a cell, particularly its nucleus, using plasmid expression vectors and nuclear localization sequences. Methods for orienting polynucleotides to the nucleus have been described in the art. Genetic material can be introduced using promoters that allow positive or negative induction of the gene of interest using a particular chemical / drug, and can be eliminated after administration of a given drug / chemical, or can be tagged to allow induction by a chemical or expression within a specific cell compartment.
[0114] Calcium phosphate transfection can be used to introduce plasmid DNA containing target genes or polynucleotides into cells and is a standard method of DNA transfer for those skilled in the art. DEAE-dextran transfection, also known to those skilled in the art, is often more efficient and may therefore be preferred over calcium phosphate transfection where transient transfection is desired. Since the cells described herein are isolated cells, microinjection may be particularly effective for transferring genetic material into cells. This method is advantageous because it delivers the desired genetic material directly to the nucleus and avoids both cytoplasmic and lysosomal degradation of the injected polynucleotides. Cells can also be genetically modified using electroporation.
[0115] Liposome delivery of DNA or RNA for genetic modification of cells can be carried out using cationic liposomes that form stable complexes with polynucleotides. Dioleoylphosphatidylethanolamine (DOPE) or dioleoylphosphatidylcholine (DOPQ) can be added to stabilize the liposome complex. A commercially available reagent for liposome transfer is Lipofectin (Life Technologies), which is, for example, a mixture of the cationic lipid N-[l-(2,3-dioleyloxy)propyl]-NNN-trimethylammonium chloride and DOPE. Liposomes can carry larger DNA fragments, generally protect polynucleotides from degradation, and target specific cells or tissues. The efficiency of cationic lipid-mediated gene transfer can be improved by incorporating purified viral or cell envelope components, such as purified G glycoprotein (VSV-G) from the vesicular stomatitis virus envelope. Using lipopolyamine-coated DNA, target DNA can be introduced into dedifferentiated or reprogrammed cells as described herein using gene transfer techniques that have been shown to be effective in delivering DNA to established primary mammalian cell lines.
[0116] Naked plasmid DNA can be injected directly into tissues containing the target cells. Microprojectile gene transfer can also be used to transfer genes into cells either in vitro or in vivo. The basic procedure for microprojectile gene transfer is described by J. Wolff in Gene Therapeutics (1994), page 195. Similarly, microparticle injection techniques have been previously described, and the methods are known to those skilled in the art. Signal peptides can also be attached to plasmid DNA to direct the DNA towards the nucleus for more efficient expression.
[0117] Viral vectors are used to genetically alter cells and their offspring, as provided and described herein. Viral vectors are used, similar to the physical methods described above, to deliver, for example, a polynucleotide sequence encoding a mechanosensitive polypeptide to a cell. Viral vectors and methods for using them to deliver or introduce polynucleotides, such as DNA or RNA, into cells are well known to those skilled in the art. Examples of viral vectors that may be used for the delivery of polynucleotides to cells, as provided and described herein, include, but are not limited to, adenovirus vectors, adeno-associated virus vectors (AAVs), retrovirus vectors (including lentivirus vectors), alphavirus vectors (e.g., Sindbis vectors), and herpesvirus vectors. In embodiments, the viral vector is a recombinant viral vector.
[0118] target cell type Mechanosensory polypeptides can be heterologously expressed in substantially any eukaryotic or prokaryotic cell of interest. In one embodiment, the cell (or target cell) is a bacterial cell or a pathogenic cell type. In another embodiment, the cell (or target cell) is a mammalian cell such as an adipocyte, muscle cell, cardiomyocyte, immune cell, insulin-secreting cell (e.g., beta(β) islet cells), or neuron (e.g., motor neurons, sensory neurons, neurons of the central nervous system (e.g., brain or brain region, e.g., hypothalamic neurons), neurons of the peripheral nervous system, interneurons, and neuronal cell lines or populations). In some embodiments, the cell is a plant cell. In some embodiments, the plant cell is neither a Dionaea muscipula nor a Drosera capensis cell.
[0119] Methods for regulating cell activity and / or function The methods provided herein are particularly useful for modulating (e.g., increasing, decreasing, suppressing, or inhibiting) the activity and / or function of cells expressing mechanesensible polypeptides. In particular, ultrasonic stimulation of such cells induces the influx or efflux of cations or anions, thereby altering the cell activity and / or function. Varying the intensity of the ultrasound modulates the degree of the change in function and / or activity.
[0120] The terms “neuron,” “neural cell,” or “nerve cell” are used interchangeably herein and refer to cells of the brain or nervous system, such as the central nervous system (CNS) or the peripheral nervous system (PNS). Non-exclusive examples of nerve cells or nerve cells include neurons, interneurons, glial cells, astrocytes, oligodendrocytes, and microglia. When nerve cells are stimulated, their function or activity (e.g., excitability) is regulated, for example, by altering the expression or activity of a given gene or protein (e.g., mechanesensory polypeptide) within the nerve cell. The change in expression or activity may be 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more compared to a control (e.g., an unstimulated cell). In certain cases, the expression or activity may be 1.5, 2, 3, 4, 5, 10, or more than the expression or activity in the absence of stimulation. In certain cases, expression or activity is 1.5 times, 2 times, 3 times, 4 times, 5 times, 10 times, or less than the expression or activity in the absence of stimulation. Neural cells can be stimulated by applying ultrasound to them.
[0121] The term “apply” as provided herein is used in its obvious and ordinary sense and includes the terms “contact,” “introduction,” and “exposure.” “Ultrasound” as provided herein is a vibrating sound pressure wave having a frequency greater than the upper limit of the human hearing range. Thus, ultrasound (ultrasound) (ultrasonic wave) is not distinguished from “normal” (audible) sound by differences in physical properties, but only by the fact that it is inaudible to humans. This limit varies from person to person, but in a healthy young adult it is about 20 kilohertz (20,000 hertz). Ultrasound (ultrasonic) devices operate at frequencies from 20 kHz to several gigahertz. The methods provided herein use the energy of ultrasound to stimulate nerve cells expressing exogenous mechanesensory proteins. Mechanosensory proteins as provided herein refer to cellular proteins that can convert mechanical stimuli (e.g., sound, pressure, motion) into chemical activity. Cellular responses to mechanesensory or mechanosensory responses are variable and produce a variety of changes and sensations. In some embodiments, mechanosensory proteins are mechanically gated ion channels that allow sound, pressure, or motion to trigger changes in the excitability of cells (e.g., sensory neurons). Stimulation of mechanosensory proteins can open mechanically sensitive ion channels, generating a transduction current that alters the cell's membrane potential.
[0122] In one embodiment, a method for stimulating cells is provided. This method comprises transfecting or transducing cells with a recombinant or viral vector containing a nucleic acid sequence encoding an exogenous (heterogeneous) mechanosensory polypeptide, wherein the transfected or transduced cells express the mechanosensory polypeptide, in particular, within the cell membrane. Ultrasound is applied to the transfected or transduced cells to stimulate them. In some embodiments, the mechanosensory polypeptide is DmFLYC1, DmFLYC2, DmOSCA, DcFLYC1.1, DcFLYC1.2, or its homolog or ortholog. In some embodiments, the mechanosensory polypeptide is the mechanosensory polypeptide, or its functional portion, homolog, or ortholog. In some embodiments, ultrasound applied to cells expressing heterologous DmFLYC1, DmFLYC2, DmOSCA, DcFLYC1.1, DcFLYC1.2 mechanesensory polypeptides or their homologs or orthologues results in a reduction, inhibition, or suppression of intracellular activity or function. In some embodiments, the ultrasound has a frequency of about 0.8 MHz to about 4 MHz. In some embodiments, the ultrasound has a frequency of about 1 MHz to about 3 MHz. In some embodiments, the ultrasound has a focal zone of about 1 cubic millimeter to about 1 cubic centimeter. In some embodiments, the ultrasound has a frequency of about 385 kHz. In some embodiments, the ultrasound has a frequency of about 10 MHz. In some embodiments, the ultrasound has frequencies of approximately 0.001 MHz, 0.01 MHz, 0.1 MHz, 0.2 MHz, 0.3 MHz, 0.4 MHz, 0.5 MHz, 1 MHz, 2 MHz, 3 MHz, 4 MHz, 5 MHz, 6 MHz, 7 MHz, 8 MHz, 9 MHz, 10 MHz, 11 MHz, 12 MHz, 13 MHz, 14 MHz, 15 MHz, 20 MHz, 30 MHz, 40 MHz, or 50 MHz.In some embodiments, the ultrasonic wave has a frequency of less than about 0.001 MHz, 0.01 MHz, 0.1 MHz, 0.2 MHz, 0.3 MHz, 0.4 MHz, 0.5 MHz, 1 MHz, 2 MHz, 3 MHz, 4 MHz, 5 MHz, 6 MHz, 7 MHz, 8 MHz, 9 MHz, 10 MHz, 11 MHz, 12 MHz, 13 MHz, 14 MHz, 15 MHz, 20 MHz, 30 MHz, 40 MHz, or 50 MHz. In some embodiments, the ultrasonic wave has a frequency of about 0.2 MHz to about 20 MHz, about 0.15 MHz to about 0.6 MHz, about 0.3 MHz to about 0.4 MHz, about 9 MHz to about 11 MHz, or about 5 MHz to about 20 MHz. In some embodiments, the ultrasonic wave is 500 mW / cm. 2 It has an intensity of less than.
[0123] In some embodiments, the ultrasonic wave is about 0.01 W / cm 2 , 0.5 W / cm 2 , 1 W / cm 2 , 5 W / cm 2 , 10 W / cm 2 , 25 W / cm 2 , 50 W / cm 2 , 100 W / cm 2 , 150 W / cm 2 , 200 W / cm 2 , 250 W / cm 2 , 3It has an intensity of less than 0.05 MPa. In some embodiments, the ultrasound generates a peak negative pressure between 0.05 and 3 MPa within the target area.
[0124] In some embodiments, ultrasound is administered to cells or tissues in pulses or bursts. In some embodiments, the pulse repetition frequency for pulses or bursts is about 0.1 Hz to about 200 Hz, or about 0.5 Hz to about 2 Hz. In some embodiments, the pulse repetition frequency is about 1 Hz. In various embodiments, ultrasound is administered in duty cycles of about 0.005% to about 100%, about 0.01% to about 50%, about 0.1% to about 10%, or about 0.5% to about 2%. In some embodiments, the duty cycle is about 1%. "Duty cycle" refers to the percentage of duration of a single on-off cycle of ultrasound administration in which ultrasound is actively administered.
[0125] In some embodiments, the method further includes bringing transfected cells or transduced cells, such as, but not limited to, nervous system cells, into contact with an ultrasound contrast agent before applying ultrasound. In various embodiments, the ultrasound contrast agent is microbubbles. In certain embodiments, the microbubbles have a diameter of about 0.1 μm, 0.2 μm, 0.3 μm, 0.4 μm, 0.5 μm, 0.75 μm, 1 μm, 1.5 μm, 2 μm, 3 μm, 4 μm, or 5 μm to about 6 μm, 7 μm, 8 μm, 9 μm, 10 μm, 50 μm, or 100 μm. In certain embodiments, the nervous system cells form part of an organism. In some embodiments, the organism is a mammal (e.g., a non-human primate, human, mouse, cattle, sheep, rodent, camel, cat, canine mammal).
[0126] Generation of acoustic energy (ultrasound) Ultrasound may be generated using a variety of devices, including acoustic and ultrasonic emitters, transducers or piezoelectric transducers, composite transducers, micro-machined ultrasonic transducers (MUTs) including capacitive micro-machined ultrasonic transducers (cMUTs), micro-electromechanical systems (MEMS), and silicon-on-insulator MEMS (SOI MEMS). Devices for generating ultrasound may be provided as single or multiple transducers or in an array configuration. The ultrasound can be of any shape and can be focused or unfocused. The size of the focal spot depends on the effective aperture diameter (A), wavelength (lambda), and focal length (F) of the probe. The central deflection of a clamped circular plate under uniform pressure can be determined from the following formula for a circular membrane. In formula TIFF2023549176000003.tif19128, P is the uniform pressure applied to the film, R is the film radius, y is the central deflection, σ is the intrinsic stress of the film material, E is the Young's modulus of the film material, and ν is the Poisson's ratio of the film material. This formula can be used to estimate the ultrasonic pressure under a given film deflection. Such emitters can be fabricated on a substrate. Multiple substrates can be combined to form a single applicator. Multiple applicators can be combined to form a single probe.
[0127] In some embodiments, ultrasound is generated by a photoacoustic system or transducer, such as those described in U.S. Patent No. 6,022,309 and U.S. Patent Application Publication No. 2005 / 0021013 (the entire disclosure thereof is incorporated herein by reference for any purpose). In some embodiments, ultrasound is generated by light energy delivered by pulsed laser light and optionally guided through an optical fiber. In some embodiments, the optical fiber is placed within a catheter. In some embodiments, the light energy is deposited in a water-based photoenergy-absorbing fluid, such as saline, a thrombolytic agent, blood, or a thrombus, generating acoustic impulses in the fluid through a thermoelastic and / or thermodynamic mechanism. By pulsing the laser at a repetition rate (e.g., 10 Hz to 100 kHz), ultrasound can be locally established within the medium. In some embodiments, a high repetition rate laser system is used to generate the light energy. In various embodiments, the laser light has a pulse frequency in the range of approximately 10 Hz to approximately 100 kHz, or approximately 20 kHz to approximately 1,000 kHz, or approximately 0.1 MHz to approximately 50 MHz, or approximately 0.1 MHz to approximately 20 MHz, or approximately 0.2 MHz to approximately 10 MHz, or approximately 1 MHz to approximately 20 MHz, or a wavelength in the range of approximately 200 nm to approximately 5,000 nm, and a pulse strength of approximately 0.01 J / cm². 2 ~About 4J / cm 2 It has an energy density within the range of [specify range]. In one embodiment, the pulse frequency is in the range of about 5 kHz to about 25 kHz. In various embodiments, the optical fiber used to deliver light energy to the fluid has a core diameter of 200 microns or 100 microns or less.
[0128] While not wishing to be constrained by theory, an absorbing fluid will thermoelastically respond to the deposition of light energy in a certain volume of composition (e.g., fluid, blood, tissue, cells, or a composition containing cells) heated by light energy, such that a high-pressure region is created within the fluid. The boundary of the high-pressure zone attenuates into a certain pattern of sound waves, with compression waves propagating away from the energy deposition region (divergent wave front) and rarefied waves propagating towards the center of the energy deposition region (converging wave front). As the rarefied waves converge towards the center of the initial deposition region, they create a region of tensile stress that facilitates the formation of a group of cavitation bubbles that bond to form larger bubbles. Ultimately, the cavitation bubbles collapse, resulting in the expansion of sound waves. The collapse and subsequent rebound of the cavitation bubbles generates sound waves in the surrounding fluid, carrying away some of the cavity's energy. The collapse and rebound processes occur on a timescale primarily governed by the fluid density and the maximum size of the initial cavity. Following the initial collapse and rebound, a series of collapse and rebound events occur that reduce the intensity until the cavity's energy dissipates in the fluid. In some embodiments, subsequent laser pulses are delivered to repeat or continue this cycle, generating ultrasound at one or more frequencies determined by the laser pulse frequency.
[0129] The pulsed laser energy sources used as described herein may, but are not limited to, be based on gases, liquids, or solid media. Examples include rare-earth doped solid-state lasers, ruby lasers, alexandrite lasers, and Nd:YAG (neodymium-doped yttrium aluminum garnet; Nd:Y3Al5O 12) lasers, and Ho:YLF (neodymium-doped yttrium lithium fluoride) lasers. One of these solid-state lasers may incorporate a nonlinear frequency doubling crystal or frequency tripling crystal to generate harmonics of the basic laser wavelength. Solid-state lasers that generate a coherent beam of ultraviolet light may be used in direct connection with the compositions and methods described herein, or may be used in conjunction with dye lasers to generate an output beam that can be adjusted over a broad portion of the ultraviolet and visible spectrum.
[0130] In one embodiment, ultrasound can be generated in a fluid by (i) depositing laser energy in a volume of fluid comparable to the dimensions of the optical fiber used to deliver the laser energy (e.g., the diameter or maximum dimension of the region where the laser energy is absorbed by the fluid) over said dimensions on a timescale shorter than the acoustic transit time (e.g., controlled by the selection of the laser wavelength and / or the absorbing fluid); (ii) controlling the laser energy such that the maximum size of the generated cavitation bubbles is approximately the same as the fiber dimensions; and (iii) pulsing the laser at a repetition rate such that multiple cycles of the process generate an acoustic emission field in the fluid. Resonant operation can be achieved by synchronizing the laser pulse repetition rate with the cavity lifetime. In some embodiments, this operation results in a fluid-based transducer that cycles at 1 to 100 kHz with a round-trip displacement of 100 to 200 μm. In various embodiments, the sound waves propagate through tissue or fluid surrounding a small amount of fluid.
[0131] In another embodiment, ultrasound can be generated in a fluid by (i) depositing laser energy into a small amount of fluid (e.g., controlled by the selection of laser wavelength and absorbing fluid) surrounded by blood vessels or tissue; (ii) controlling the laser energy such that the maximum size of the vapor bubbles generated is approximately the same as or smaller than the diameter of the blood vessel or the surrounding tissue in which the vapor bubbles are generated; and (iii) pulsing the laser energy at a repetition rate such that multiple cycles of the bubble generation and collapse process generate sound waves in the fluid. In various embodiments, the sound waves propagate through the tissue or fluid surrounding the small amount of fluid.
[0132] Methods of treatment and cell manipulation In one embodiment, a non-invasive therapeutic method is provided and described, which involves the use of sound waves (ultrasound) to activate mechanosensitive transmembrane proteins (mechanoreceptors) that stimulate, increase, suppress, or inhibit cellular function locally and / or downstream of the initial source of ultrasound application. In another embodiment, a method is provided for altering the function of sensory units innervating a target tissue portion of an animal. In yet another embodiment, a method is provided for manipulating the activity or function of cells or tissues, particularly mammalian cells or tissues including human cells or tissues, or plant cells or tissues. In one embodiment, the plant is neither Dionaea muscipula nor Drosera capensis. The method involves the expression of heterologous polypeptides within cells. This method comprises expressing a therapeutically effective amount of exogenous mechanesensible polypeptide (e.g., DmFLYC1, DmFLYC2, DmOSCA, DcFLYC1.1, and DcFLYC1.2) in target cells or tissues, and applying ultrasound to the target, cells, or tissues to induce a change in mechanesensible polypeptide conductance, e.g., influx or efflux of cations or anions, within the cells or tissues. In one embodiment, this method comprises administering or delivering a therapeutically effective amount of recombinant nucleic acid, vector, or viral vector encoding exogenous mechanesensible polypeptide (e.g., DmFLYC1, DmFLYC2, DmOSCA, DcFLYC1.1, and DcFLYC1.2) to target cells or tissues, and applying ultrasound to the cells or tissues to induce a change in mechanesensible polypeptide conductance, e.g., influx or efflux of cations or anions. In one embodiment, the method is used to manipulate tissue or cells ex vivo, in vivo, in situ, or ex situ. In one embodiment, the method includes treating or improving a disease or disorder by modulating, for example, enhancing, increasing, suppressing, or inhibiting cellular activity or function in a subject having a disease or disorder.In certain embodiments, the exogenous mechanesensible polypeptide is a mechanesensible polypeptide, namely DmFLYC1, DmFLYC2, DmOSCA, DcFLYC1.1, DcFLYC1.2, its orthologue or homolog, or a functional part thereof.
[0133] In some embodiments, the method further comprises administering an ultrasound contrast agent to the subject, cells, or tissue before applying ultrasound to the subject, cells, or tissue. In some embodiments, the ultrasound contrast agent is microbubbles. In some embodiments, the microbubbles have a diameter of about 0.1 μm, 0.2 μm, 0.3 μm, 0.4 μm, 0.5 μm, 0.75 μm, 1 μm, 1.5 μm, 2 μm, 3 μm, 4 μm, or 5 μm to about 6 μm, 7 μm, 8 μm, 9 μm, 10 μm, 50 μm, or 100 μm, and are injected into or otherwise introduced into a body (e.g., brain), tissue, cells, plant, or culture medium containing tissue or cells that enhance the ultrasound stimulation.
[0134] In various embodiments, the method involves delivering or applying acoustic energy (ultrasound) to a targeted tissue or cell. Generally, the delivery or application of acoustic energy to a targeted tissue or cell is non-invasive. In some embodiments, the target tissue or cell forms part of a sensory unit. In various embodiments, the tissue or cell is configured to express an acoustically sensitive transmembrane protein, e.g., an exogenous or heterologous acoustically sensitive transmembrane protein, so that when the tissue or cell is exposed to acoustic energy, the membrane potential of the cell, including the tissue, is regulated at least in part due to the exposure of the acoustically sensitive protein to the acoustic energy. The tissue or cell may be genetically or recombinantly modified to express an acoustically sensitive transmembrane protein. The acoustically sensitive transmembrane protein may be selected from DmFLYC1, DmFLYC2, DmOSCA, DcFLYC1.1, DcFLYC1.2, or their orthologs or homologs.
[0135] The acoustic source may be selected from, in non-limiting examples, piezoelectric transducers, e.g., PZT-based transducers, composite transducers, microfabricated ultrasonic transducers, capacitive microfabricated ultrasonic transducers, and microelectromechanical systems. The acoustic source may include silicon-on-insulator type microelectromechanical systems. In some embodiments, acoustic energy is delivered transcutaneously from the acoustic source. In some embodiments, acoustic energy is delivered transcranially. In some embodiments, the tissue or cells are located in the brain of the subject, e.g., the hypothalamus. In some embodiments, the tissue or cells constitute part of the central nervous system. In some embodiments, the tissue or cells constitute part of the peripheral nervous system. In some embodiments, the acoustic source is located on or within the tissue or organ of the subject or plant. In some embodiments, the acoustic source is located on or within the brain of the subject. In certain embodiments, nerve cells, such as motor neurons, expressed in one region, for example in the spinal cord, with the acoustically sensitive heterogeneous mechanosensory proteins described herein, are stimulated with acoustic energy (ultrasound), resulting in activation, inhibition, or suppression of nerve cells, such as motor neurons, in another region, for example in downstream muscle tissue. In some embodiments, the method involves using multiple acoustic emitters to activate the target cells or tissues. In embodiments, the cells are neurons in the spinal cord and / or downstream muscles, such as motor neurons.
[0136] In one embodiment, a method for neuromodulation based on ultrasound genetics in a patient is provided. In some embodiments, the method involves determining the functional modulation of a desired nervous system, which can be facilitated by ultrasound genetic stimulation and / or inhibition. The method may further involve the selection of neuroanatomical resources within the patient to provide such results. The method may involve causing the cells of the neuroanatomical resources to become sensitive to acoustic energy. The method may further involve delivering acoustic energy to a targeted neuronatomy to induce controlled, specific stimulation and / or inhibition of such neuronatomy due to the presence of mechanosensory proteins in its cells. In some embodiments, the mechanosensory proteins modulate the membrane potential of a neuron or other type of cell by transporting ions, such as potassium, sodium, calcium, chloride, bromide, fluoride, or iodide ions, across the cell membrane.
[0137] The embodiments and practices described herein utilize, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry, and immunology, which are within the scope of those skilled in the art. Such techniques are fully described in literature such as “Molecular Cloning: A Laboratory Manual”, second edition (Sambrook, 1989), “Oligonucleotide Synthesis” (Gait, 1984), “Animal Cell Culture” (Freshney, 1987), “Methods in Enzymology” “Handbook of Experimental Immunology” (Weir, 1996), “Gene Transfer Vectors for Mammalian Cells” (Miller and Calos, 1987), “Current Protocols in Molecular Biology” (Ausubel, 1987), “PCR: The Polymerase Chain Reaction” (Mullis, 1994), and “Current Protocols in Immunology” (Coligan, 1991). These techniques are applicable to the production of polynucleotides and polypeptides described herein and can therefore be considered in the preparation and implementation of the described embodiments and models. Techniques particularly useful for specific embodiments are described in the following sections.
[0138] The following examples are provided to provide a complete disclosure and explanation of how to prepare and use the assays, screenings, and therapeutic methods described herein, and are not intended to limit them.
[0139] Compositions and pharmaceutical compositions This specification provides compositions comprising cells expressing heterologous or exogenous mechanesensory polypeptides described herein. In one embodiment, the composition is a pharmaceutical composition. Typically, the carrier or excipient for such a composition is a pharmaceutically acceptable carrier or excipient such as sterile water, saline, buffered saline, aqueous dextrose solution, aqueous glycerol solution, ethanol, or a combination thereof. The preparation of such solutions, ensuring sterility, pH, isotonicity, and stability, is influenced according to protocols established in the art. Generally, the carrier or excipient is selected to minimize allergic and other undesirable effects and to be suitable for specific routes of administration, e.g., subcutaneous, intramuscular, intranasal, etc.
[0140] A composition or pharmaceutical composition is administered in a dose or effective dose that improves, reduces, decreases, alleviates, soothes, or eliminates the effects of a disease, disorder, or condition and / or its symptoms. The composition may be provided in dosage forms suitable for parenteral administration routes (e.g., subcutaneous, intravenous, intramuscular, subarachnoid, or intraperitoneal). Pharmaceutical compositions may be formulated and prepared according to conventional pharmaceutical practice (see, for example, Remington: The Science and Practice of Pharmacy (20th ed.), ed. ARGennaro, Lippincott Williams & Wilkins, 2000 and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and JCBoylan, 1988-1999, Marcel Dekker, New York). Pharmaceutical compositions may be administered parenterally by injection, infusion, or implantation (e.g., subcutaneous, intravenous, intramuscular, intraperitoneal, subarachnoid). Compositions for parenteral use may be provided in unit dosage forms (e.g., single-dose ampoules) or in vials containing several doses, to which suitable preservatives may be added (see below). Compositions may be in the form of solutions, suspensions, emulsions, infusion devices, or implantation delivery devices. [Examples]
[0141] Example 1: Discovery of FLYCATCHER1 and FLYCATCHER2 (FLYC1 and FLYC2), and DmOSCA Venus flytraps have evolved rapid contact-induced movement. Bending of any one of the Venus flytrap's sensory hairs generates an action potential in the sensory cells at the base of the hair, which propagates through the trap and correlates with an increase in cytoplasmic calcium in the leaf trap cells. Early recordings from Venus flytraps suggest that, based on the timescale of action potential generation, mechanosensible ion channels may play a role in transmitting force to electrical signals. To identify the ion channels that may be necessary for the Venus flytrap's contact response, efforts were initiated to find genes preferentially expressed in the sensory hairs.
[0142] The Venus flytrap genome is extremely large, approximately 20 times larger than that of the commonly studied model plant Arabidopsis thaliana (Table 1), and no inbred lines are available. Therefore, a clonal breeding system was established for the collection of genetically identical material (Figures 1A, 1B, 7A, and 7B). Using these clones, a de novo transcriptome representing the genes expressed in trap tissue was generated from Illumina-based short sequencing reads. The transcriptomes of the clonal strains consisted of nearly 28,000 unique transcripts, each with an open reading frame encoding a predicted protein of at least 100 amino acids. This is larger than the approximately 21,000 genes previously predicted by genome sequencing and reflects the presence of multiple isoforms within the transcriptome, potential heterozygosity and strain differences, and / or differences in genomic / transcriptome completeness, as shown by BUSCO analysis (see Materials and Methods). Comparing the transcriptome of plant sensory hairs with that of leaf traps alone, 495 protein-coding genes were differentially enriched more than twice in sensory hairs, while 1,844 protein-coding genes were similarly enriched in the traps. Based on homology with Arabidopsis, many genes preferentially expressed in leaf traps were associated with photosynthetic function, but genes more highly expressed in sensory hairs included transcription factors and genes that may affect cell and organ structure.
[0143] [Table 1]
[0144] To identify potential mechanosensitive ion channels, the enriched transcriptome in sensory hairs was screened for transcripts encoding likely multi-pass transmembrane proteins. Of 45 such transcripts, three encoded potential candidates based on homology to Arabidopsis proteins. Two of these shared homology with MSL family proteins (transcript IDs: comp2014_c0_seq1 and comp28902_c0_seq1), and one with the OSCA family (comp16046_c0_seq1). These genes were named FLYCATCHER1 and FLYCATCHER2 (FLYC1 and FLYC2), and DmOSCA, respectively. No enriched expression of homologs to mechanically activated PIEZO channels was observed. One of these MSL-related transcripts, FLYC1, was expressed 85-fold higher in sensory hairs than in trapping tissue (Figure 1C and Figure 1D), making it the second most enriched gene (the putative terpene synthase was enriched 176-fold; see Materials and Methods). In contrast, the other two putative ion channels were expressed differentially at less than 7-fold. To validate the transcriptome, the transcript sequence from the cDNA of FLYC1 was validated using Sanger sequencing to determine the complete gene sequence. The absence of single nucleotide polymorphisms (SNPs) causing amino acid changes in the exons of the strain was determined to indicate protein product selection (Materials and Methods).
[0145] Example 2: Structure, sequence, and phylogenetic analysis of FLYC1, FLYC2, and DmOSCA FLYC1 and FLYC2 encoded predicted proteins of 752 and 897 amino acids, respectively, with homology to Arabidopsis MSL10 and MSL5 (Figure 2A). Ten MSL (MscS-like) proteins were previously discovered in Arabidopsis based on their similarity to MscS, a low-conductance bacterial mechanosensible channel. While we do not wish to be bound by theory, in Escherichia coli, the opening of MscS allows for ion release during osmotic down shock and cell swelling, thereby preventing cell rupture. In Arabidopsis, MSL8 functions in pollen rehydration, but the role of the remaining MSLs in mechanosensory physiological processes is unclear. When heterologously expressed in African clawed frog (Xenopus laevis) oocytes, MSL10 forms a slightly chloride-preferring functional mechanosensible ion channel. Furthermore, along with other members of the MSL family, MSL10 explains the extension-activated current recorded from root protoplasts. FLYC1 and FLYC2 were 38.8% identical, sharing 47.5% and 35.5% identity with MSL10, respectively, with most mutations in the cytoplasmic N-terminus. Compared to MscS, FLYC1 and FLYC2 had three additional predicted transmembrane helices, totaling six, and the C-terminus of the proteins shared the highest homology (Figures 2B and 2C).
[0146] DmOSCA encodes a predicted 754-amino acid protein with the highest homology (64% identity) to Arabidopsis OSCA1.5, belonging to the 15-member family of Arabidopsis OSCA proteins (Figures 2D and 2E). While initial identification characterized the OSCA family as hyperosmotically activated calcium channels, several members of the OSCA family have been demonstrated to be mechanosensible ion channels that are non-selective to cations and possess some chloride permeability. Tmem63, an ortholog in flies and mammals, also encodes a mechanosensible ion channel, suggesting that the molecular function of OSCA genes is conserved. Furthermore, purification and reconstitution of AtOSCA1.2 in proteoliposomes induced extension-activated currents, indicating that these proteins are inherently mechanosensible. Notably, mutant OSCA1.1 plants may exhibit inhibited leaf and root growth when exposed to hyperosmolar stress, resulting from impaired mechanotransduction in response to changes in cell size. This suggests that, like the MSL family, these channels may have played an ancestral role as osmotic sensors.
[0147] Example 3: Identification of cells expressing FLYC1, FLYC2, and DmOSCA Experiments were conducted to identify cells in sensory hairs expressing the FLYC1, FLYC2, and DmOSCA genes. Sensory hairs can be divided into two main regions: the cuticinated liver and the petiole where the liver is located. A depression zone at the top of the petiole separates the two regions (Figures 3A and 3C). This zone is where most of the bending of the sensory hair occurs. Electrophysiological recordings demonstrate that mechanical stimulation of the sensory hair generates action potentials from a monolayer of sensory cells in this depression zone, rather than from other cells in the petiole or liver. Fluorescence in situ hybridization specifically detected the FLYC1 transcript in sensory cells of the depression zone (Figures 3B, 3C, and 3D). The transcript was not observed in cells of the liver or lower petiole (Figures 3B and 3E). In contrast, the housekeeping gene EF1α transcript was detected throughout the sensory hair and trap (Figures 8A and 8B). The FLYC1 sense probe did not generate a signal on the background (Figure 3B). Using a similar in-situ hybridization method, the FLYC2 transcript was not detected, but DmOSCA was found at high levels in sensory hair cells, but at low levels in other cell types (Figures 9A and 9B). These results are consistent with RNA-seq findings from whole sensory hairs, where FLYC2 and DmOSCA were not as enriched in background trap tissue compared to FLYC1, and in the case of FLYC2, they were only weakly expressed (Figure 1D). Nevertheless, the expression profiles of FLYC1 and DmOSCA were consistent with these genes being located at the contact-inducible initiation site of action potentials, resulting in trap closure.
[0148] Example 4: Exogenous expression of FLYC1, FLYC2, and DmOSCA in HEK-P1KO cells To test whether FLYC1, FLYC2, and DmOSCA are mechanically activated ion channels and conferred mechanosensibility to naive cells, human codon-optimized polynucleotide sequences of these genes were exogenously expressed in mechanically insensitive HEK-P1KO cells. When negative pressure was applied to the recording pipette in a cell adhesion patch configuration, robust stretch-activating currents were recorded from FLYC1-expressing cells (Figures 4A and 4B), but not from FLYC2- or DmOSCA-expressing cells (Figure 10). In these experiments, overexpression of human codon-optimized MSL10 and subcloned OSCA1.5 subcloning did not generate stretch-activating currents within the system using HEK-P1KO cells (Figure 10). While not intended to be theoretically bound, MSL10 expression in oocytes has been shown to induce stretch-activating currents, and therefore, the transport of these plant proteins may be impaired after expression in mammalian cells. As will be understood by those skilled in the art, modifications to polynucleotide expression techniques, the conditions used to express plant proteins in HEK-P1KO, the use of other expression systems and host cells, and / or further codon optimization can result in functional extensional activation currents from certain of these exogenously expressed plant-derived proteins. Considering its high transcript enrichment, localization in sensory cells, and mechanosensibility, FLYC1 was selected as a promising functional mechanosensor in Venus flytrap sensory hairs.
[0149] Further characterization of the FLYC1 channel properties showed that stretch-induced FLYC1 activation occurred at -70±4 mmHg (N=9), and the channel had a conductance of 164±9 pS (N=6) (Figure 4C). Similar to the MSL10 stretch-activation current in oocytes, the FLYC1 current had a slow rise time for activation and did not saturate, suggesting that these channels were not inactivated. Upon removal of the stretch stimulus, the current decayed with a time constant of 167±34 ms (N=5). While we do not wish to be bound by theory, in terrestrial plants and green algae, chloride-permeable channel openings are associated with membrane depolarization due to the efflux of chloride ions under an electrochemical gradient. Therefore, we tested whether FLYC1 is permeable to chloride by recording the stretch-activated FLYC1 current from a cleaved patch in an asymmetric NaCl solution. FLYC1 showed a P of 9.8±1.8 (N=7) Cl / P Na It has been demonstrated that chloride is preferable to sodium with a ratio (Figures 4D and 11), and this ratio is MSL10(P Cl / P Na :5.9) and MscS(P Cl / P K The ratios for :1.2~3.0 were higher than those previously obtained.
[0150] Example 5: Evaluation of pore-lining helix While bacterial MscS is known to be a mechanically activated ion channel gated by membrane tension, little is known about the structure and function of plant MSLs. Homology modeling of MSL10 using MscS has shown specific residues that alter channel conductance, but the molecular determinants of selectivity and gating in MSL10 remain largely unknown. Due to the high sequence similarity of the C-terminuses of MscS, MSL10, and the FLYC1 protein (Figure 12A), we assessed the extent to which the molecular structure of the proposed inner pore helix is shared among these channels. Homology modeling of FLYC1 with a known MscS structure suggested that certain features of the pore-forming transmembrane domain (TM6) are conserved. These include hydrophobic residues within the helix portion with the inner pore (TM6a), and a glycine kink at G575, followed by an amphiphilic helix (TM6b) parallel to the inner plasma membrane surface (Figures 12B and 12C). Based on the results showing that FLYC1 prefers chloride, we tested whether positively charged lysine residues on both sides of the predicted pores (K558 and K579) could confer pore properties. We substituted the lysine residues at positions 558 and 579 with glutamic acid residues, and P Cl / P Na The following measurements were taken. Chloride selectivity remained unchanged in both mutants, but the K579E mutant showed a smaller single-channel current at positive membrane potential (Figure 12D), suggesting that K579 was located near the pore. This analysis confirmed that the predicted TM6 of FLYC1 is part of the inner pore region of the channel, consistent with the mutagenesis results in MSL10. These findings were further supported by cryo-EM (electron microscopy) structure of AtMSL1, which showed a similar architecture of the channel's final transmembrane (TM).
[0151] Example 6: Exogenous expression of DcFLYC1.1 and DcFLYC1.2 Due to the importance of FLYC1 for contact-induced prey recognition, we hypothesized that the expression and function of FLYC1 in mechanosensory structures are conserved across carnivorous Droseraceae plants. To test this hypothesis, we investigated Drosera, which includes approximately 200 species of sundews, the largest genus in the family. Sundews are characterized by contact-sensing projections on their leaf surface called tactile hairs (Figure 5A). These tactile hairs typically secrete a sticky mucus from their heads, which acts as a trapping adhesive when an insect prey comes into contact with them. When the trapped insect moves, action potentials are generated along the tactile hairs, causing them to move radially, often toward the center of the leaf. This allows for the trapping of the struggling insect by more mucus-secreting tactile hairs, enabling digestion to occur (Figure 5B).
[0152] Expression of two FLYC1 homologs in Drosera capensis was identified by quantitative reverse transcriptase-(qRT-)PCR. Consistent with findings from experimental studies of Venus flytraps, these two transcripts were expressed 30-40 times more in the tentacles compared to leaf tissue without tentacles (Figure 5C). Cloned cDNAs of these two genes (named DcFLYC1.1 and DcFLYC1.2) encoded nearly identical predicted protein products with 96.4% identity. They shared 66.2% and 65.6% identity with Venus flytrap FLYC1, respectively (Figure 2A).
[0153] The antennae of *Drosera rotundifolia* vary in length depending on their position on the leaf (Figures 13A and 13B), but share a similar mechanosensory head structure with two outer layers of secretory cells (Figure 5D). Previously, it was hypothesized that the outermost secretory cells would double as the antennal region. These cells are not only directly exposed to the mucus environment from which prey insects adhere and pull, but also exhibit unique morphology: outer cell wall buttresses and cracks in the plasma membrane (Figure 14). Furthermore, cellulose fibrils extend from the outer cell wall into the cuticle, much like the depression zone of *Venus flytrap*. SmFISH probes for DcFLYC1.1 and DcFLYC1.2 transcripts were localized to the outer secretory cells, but no transcripts were observed in the leaves at the base of the antennae (Figure 5E).
[0154] Heterogeneous expression of human codon-optimized DcFLYC1.1 and DcFLYC1.2 cDNAs, independently or collectively, did not result in extension activation currents in HEK-P1KO cells (Figure 15). Similar to the findings for DmFLYC2 and DmOSCA, the lack of activity may be due to misfolding and transport of these proteins. Technical difficulties in live-labeling these ion channels limit our ability to present evidence for this (see Materials and Methods). Nevertheless, the expression data are consistent with the conserved role of FLYC1 in two different species of carnivorous Droseraceae plants.
[0155] Materials and methods related to Examples 1-6 Plant raw materials and growth conditions Venus flytraps were propagated in tissue culture using a modified method from a previously described method (Jang, GW, Kim, KS, & Park, RD (2003) “Micropropagation of Venus fly trap by shoot culture” Plant Cell Tissue and Organ Culture, 72(1), 95-98). Seeds (FlytrapStore.com, OR) were surface sterilized with 0.1% Triton X-100 and 70% ethanol for 5 minutes, rinsed, and then seeded in 1 / 3 × Murashige and Skoog (MS) salt and vitamin (Caisson Labs), 3% sucrose, and 4.3 g / L gellan gum. After germination, plants were selected for robust growth in tissue culture and on a large scale to facilitate tissue manipulation. Single strains derived from a single seed (CP01) were selected for further propagation by sequential division of the rhizome. After 9-12 months of cultivation, the largest rosettes were transferred to soil (fine-grade sphagnum peat moss) and grown under greenhouse conditions (25-30°C, approximately 16 hours of light, 8 hours of darkness, with artificial red light added overhead at night to bring the total light duration to 16 hours). The soil was kept constantly moist with purified water. The plants were hardened on the soil for at least 2-3 months prior to the experiment.
[0156] Drosera capensis var. rubra (Cape sundew) seeds (AK Carnivores, HI) were surface-sterilized, germinated on plates, and seedlings were transplanted into soil and cultivated under greenhouse conditions.
[0157] For imaging of cell wall-stained tissue sections, freshly collected plant tissue was dissected in 50 mmol / L Pipe Buffer (pH 7.2) with 2% (v / v) paraformaldehyde and 1.25% (v / v) glutaraldehyde, and fixed in the same solution for 2 hours (h). The samples were dehydrated in a stepwise ethanol series and embedded in JB-4 Plus Embedding Media (Electron Microscopy Sciences) according to the manufacturer's instructions. However, infiltration was performed at room temperature over 7 days. Several dehydrated samples were then stained with 0.1% eosin in 100% ethanol to aid in visualization of the material during sectioning, and then embedded. Sections were cut to 4–6 μm and dried on Probe On Plus slides (ThermoFisher Scientific) from drops of dH2O. Tissue sections were stained with 0.01% aqueous toluidine blue O, covered with coverslips, and examined under an Olympus BX51 microscope.
[0158] Scanning electron microscopy (SEM) was performed using a field-spectrum scanning electron microscope (Sigma VP; Zeiss) in variable pressure mode, imaging fresh plant tissue at 5 Pa of nitrogen with a variable pressure secondary electron detector.
[0159] For time-lapse videos and optical images of D. capensis during feeding, plants were fed with Drosophila melanogaster (Canton-S) or houseflies (Musca domestica), and images were captured using an Olympus Tough TG-5 camera. To assist with feeding, all insects were temporarily paralyzed by placing them in tubes on ice for 5-10 minutes immediately before feeding them to the plants.
[0160] Estimation of nuclear genome size Nuclear genome size was estimated using the same flow cytometry method as previously reported (Arumuganathan, K., & Earle, ED, 1991, Plant Molecular Biology Reporter, 9(3), 229-241. doi:10.1007 / bf02672073) and performed at Benaroya Research Institute (Seattle, WA). 50 mg of nuclei from Arabidopsis leaves or Venus flytrap petiole tissue were suspended in a 0.5 mL solution of 10 mM MgSO4, 50 mM KCl, 5 mM Hepes (pH 8.0), 3 mM dithiothreitol, 0.1 mg / mL propidium iodide (PI), 1.5 mg / mL DNAse free RNAse (Roche), and 0.25% Triton X-100. The nuclei were filtered through a 30 μm nylon mesh and incubated at 37°C for 30 minutes. Stained nuclei were analyzed using a FACScalibur flow cytometer (Becton-Dickinson). As an internal standard, the sample contained nuclei from chicken erythrocytes (2.5 pg / 2C). For each measurement, PI fluorescence area signals (FL2-A) were collected and analyzed from 1000 nuclei, and the average position of the G0 / G1 peaks in the sample and internal standard was determined using CellQuest software (Becton-Dickinson). The estimated nuclear DNA size is the average of the four measurements.
[0161] Tissue collection for RNA-seq and qRT-PCR To generate an RNA-seq library from sensory hair tissue, sensory hairs were collected under artificial red light 3-4 times a week for one month, between 6:30 and 9:30 pm. Only traps with a length greater than 1.5 cm were used. Twelve sensory hairs were cut from the surface of two leaves at a time before rapid freezing in liquid N2 (less than 5 minutes between cutting and freezing). Aliquots of the sensory hairs were pooled during subsequent RNA extraction. Samples from traps from which sensory hairs had been removed (approximately 20) were collected simultaneously as comparison tissues. The experiment was performed three times. 250 sensory hairs were collected in the first experiment, and 750 sensory hairs were collected in the second and third experiments, respectively.
[0162] For both fed and unfed trap samples, each tissue sample contained two traps (over 1.5 cm in length), each fed with one housefly for 24 hours. The fed traps were opened at the time of collection, and the dead flies were removed before rapid freezing of the tissue. Samples were collected twice.
[0163] The tentacle hairs of *Drosera rotundifolia* were collected by removing fresh leaves from the plant and placing them directly into liquid N2. While immersed in liquid N2, the leaves were agitated and / or rubbed to tear off the tentacle hairs. The tentacle hairs and remaining leaf material were then separated and RNA extracted. Each sample type was collected four times.
[0164] RNA extraction for qRT-PCR and RNA-seq Total RNA was extracted using a modified LiCl-based method similar to those described elsewhere (Bemm, F. et al., 2016, Genome Res, 26(6), 812-825.doi:10.1101 / gr.202200.115, Jensen, MK et al., 201), PLoS One, 10(4), e0123887.doi:10.1371 / journal.pone.0123887). Briefly, frozen plant material was pulverized into a powder and 700 μL of RNA extraction buffer (2% CTAB, 2% polyvinylpyrrolidone K25, 100 mM Tris HCl pH 8.0, 25 mM Na-EDTA pH 8.0, 2 M NaCl, 2% v / v β-mercaptoethanol) was added. If necessary, tissue aliquots were pooled at this stage or after ethanol precipitation. The sample was vortexed for 2 minutes, then incubated at 65°C for 10 minutes, vortexing occasionally. Debris was removed by centrifugation, and 600 μL of chloroform was added to the supernatant and mixed. The sample was centrifuged at 10,000 rpm for 10 minutes. 1 / 3 vol of 7.5 M LiCl was added to the aqueous phase, then gently mixed and incubated overnight at 4°C. The RNA was pelletized by centrifugation at 10,000 rpm at 4°C for 10 minutes. The RNA pellet was washed with 70% ethanol, air-dried, and resuspended in 100 μL of H2O. For low-yield samples, the RNA was then reprecipitated by adding 0.1 vol of 3 M NaAcetate (pH 5.2), 2.5 vol of 100% ethanol, and optional 1.5 μL of GlycoBlue (Thermo Fisher), mixing, and incubating at -80°C for 1 hour. RNA was pelletized by centrifugation at 12,000 rpm for 20 minutes at 4°C. The pellets were washed with 70% ethanol, air-dried, and resuspended in 30-50 μL of H2O. These samples were then used directly to generate cDNA for qRT-PCR. Alternatively, RNA-seq samples were resuspended in 22 μL of H2O, to which 2.5 μL of 10x TURBO buffer and 1 μL of TURBO DNase (Thermo Fisher) were added. The samples were incubated at 37°C for 20-30 minutes.Next, 2.5 μL of inactivation reagent was added, and the sample was incubated at room temperature for a further 5 minutes, with occasional mixing. The resin was removed by centrifugation at 10,000 rpm for 1.5 minutes, and the supernatant was transferred to a new tube. RNA quality and yield were evaluated using Agilent's TapeStation before proceeding with the generation of the sequencing library.
[0165] RNA-Seq and Venus flytrap transcriptome assembly Stranded mRNA-Seq libraries were prepared using the Illumina TruSeq Stranded mRNA Library Prep Kit according to the manufacturer's instructions. Libraries were quantified, pooled, and sequenced using paired-end 125bp reads on the Illumina HiSeq2500 platform in Salk NGS Core. The raw sequencing data were demultiplexed and converted to FASTQ files using CASAVA (v1.8.2). All samples were sequenced simultaneously on a single flow cell lane. The average sequencing depth was 8.8 million reads per library. Library quality was assessed using FastQC (v0.11.5) and Illumina adapter sequences, and low-quality reads trimmed using Trimmomatic (0.36.0) were trimmed with parameters recommended by Trinity (a widely used application for generating de novo transcriptomes in the art).
[0166] Most aspects of de novo transcriptome assembly and RNA-Seq analysis were performed using the CyVerse cybercomputing infrastructure (S. Goff et al., 2011, Frontiers in Plant Science, 2, doi:10.3389 / fpls.2011.00034). To obtain the most complete representation of the Venus flytrap transcriptome, the trap transcriptome was constructed by including reads collected from houseflies fed and unfed traps, in addition to pairs of sensory hair trap samples and non-sensory hair trap samples (Table 2). Trinity (v2.5.1) was used for the de novo build with default settings and assembled contig lengths exceeding 300 nt. The final transcriptome contained 80,592 contigs, which were grouped into 77,539 components. Hereinafter, each Trinity component is generally referred to as a “gene”. The maximum bond length was 15,873 nt, while the mean and median were 867 nt and 536 nt, respectively, and N50 was 1,197 nt.
[0167] [Table 2]
[0168] The completeness of the Venus flytrap transcriptome was assessed using CEGMA (Core Eukaryotic Genes Mapping Approach) and BUSCO (Benchmarking Universal Single-Copy Orthologs) analysis. Using CEGMA, all of the 248 hyperconserved core eukaryotic genes were present in the transcriptome, and 246 of these coding sequences were defined as complete according to the CEGMA criteria. A search for the presence of nearly universal single-copy orthologs using BUSCO (v3.0; phylogenetic: plantae; species: Arabidopsis) showed that 94.7% of BUSCO were present, and 92.6% of these were defined as complete. This number is greater than the number previously reported for publicly released Venus flytrap genome sequences (Palfalvi, G. et al., 2020, Curr Biol, 30(12), 2312-2320 e2315, doi:10.1016 / j.cub.2020.04.051).
[0169] To further test the transcriptome quality, Bowtie2 (v2.2.4) was used to return the read values of each sample to the transcriptome. For each sample, 80–90% of the paired read values matched and mapped, but the overall alignment rate was over 90%. These values were similar when the reads of each sample from the second sequencing run were independently aligned.
[0170] Using TransDecoder(v1.0), we identified open reading frames (ORFs) on the + chain that encoded potential proteins or incomplete protein fragments with a length of at least 100 amino acids. In total, we found 33,710 ORFs that met these criteria (this number increased only slightly to 34,080 when the - chain was included). Of these, 14,886 were confirmed to be complete. These values are similar to those previously reported for Venus flytrap transcriptomes generated from multiple tissues (Jensen, MK et al., (2015), Transcriptome and genome size analysis of the Venus flytrap, PLoS One, 10(4), e0123887.doi:10.1371 / journal.pone.0123887).
[0171] To assign homologous sequences from Arabidopsis to protein-coding transcripts, complete and partial polypeptides were blasted against the Arabidopsis TAIR 10 proteome using the default settings of Blastp (v2.2.29), with an e-value threshold of less than 0.01. Top hits were retained only for downstream analysis. TMHMM v.2.0 was used to predict the number of transmembrane layers per protein.
[0172] The de novo flytrap transcriptome is available from the National Center for Biotechnology Information (NCBI) Transcriptome Shotgun Assembly (TSA) database, with accession number GHJF00000000. The uploaded transcriptome has the following modifications from the above and is used for the following differential gene expression analysis: the last 42nt contig comp11005_c0_seq1 and the first 21nt comp46326_c0_seq1 (possible adapter sequence) have been removed, and 18 contigs have been flagged and deleted as possible contaminants. The uploaded transcriptome contains 80,574 contigs.
[0173] RNA-seq differential gene expression analysis The method supported by Trinity was used to find differentially expressed genes between sensory hair trap tissue samples and trap tissue samples without sensory hairs. A second sequencing run was performed on all samples to increase the sequencing read count across any given contig (SRA accession numbers: SRR8834210, SRR8834209, SRR8834208, SRR8834207, SRR8834212, and SRR8834211). The concatenated reads were trimmed from both sequencing runs using Trimmomatic as described above, and these were aligned to the de novo flytrap transcriptome using Bowtie. RSEM (v1.2.12) was used to find expected gene counts, and edgeR was used to find differentially expressed genes using a paired experimental design for statistical testing. For analysis in edgeR (v3.12.1), the gene list was initially screened to include only Trinity components containing transcripts with open reading frames (ORFs) encoding proteins (or fragments thereof) of at least 100 amino acids in length. For components to which multiple such proteins were assigned, the longest ORF was assumed to be the most relevant and used as the basis for assigning Arabidopsis homologs to the gene / component. Genes with fewer than 2 counts / million (CPM) in more than half of the samples were excluded from the analysis. A table of genes passing these criteria, showing gene expression values as mean CPM in traps and sensory hairs, and differential expression between sensory hairs and traps calculated using the edgeR algorithm with false detection rate (FDR), can be found in the NCBI Gene Expression Omnibus (GEO) database with GEO series accession number GSE131340. This repository also contains a list of all protein-coding genes and BLAST results for the Arabidopsis proteome. In addition to FDR < 0.05, genes with a 2-fold or greater enrichment difference were designated as those that induce hair or trap enrichment expression.The enrichment ratio was calculated using the edgeR algorithm, rather than directly from the mean CPM value. For gene ontology (GO) analysis, GO terms were assigned to each gene based on its homologous Arabidopsis protein (Arabidopsis TAIR10 annotation data were downloaded in April 2018). GO enrichment was performed using BiNGO 3.03 (biological process terms only) with Benjamini and Hochberg corrected p-values < 0.05.
[0174] Within the sensory hair transcriptome, the most differentially expressed gene encoded a protein homologous to terpene synthase (transcript ID: comp18811_c0_seq1; approximately 175-fold enrichment). The expression of this gene may be a remnant of an evolutionary history suggesting that sensory hairs evolved from ancestral tactile secretory structures. However, enrichment of other genes clearly related to volatile production was not observed. Blasting the transcript against the Arabidopsis TAIR10 genome reported a hit to Arabidopsis MSL10 due to a conserved 17nt elongation. Therefore, a common regulatory sequence may exist between this transcript and MSL-related genes.
[0175] Cloning of Venus flytrap cDNA and sequencing of DmFLYC1 genomic DNA. cDNA from all Venus flytrap trap tissues was prepared from RNA using the Maxima First Strand cDNA Synthesis Kit (Thermo Fisher). The FLYC1 cDNA (Trinity ID#comp20014_c0_seq1) was then PCR amplified using primers CP1010 and CP1011 (Table 3) that annealed at the predicted 5' and 3' UTRs, and ligated to pCR-Blunt II-TOPO (Invitrogen). Clones matching the predicted sequence from the de novo transcriptome were generated, as evaluated by Sanger sequencing. Similarly, EF1α (comp10702_c0_seq1) was PCR amplified from the cDNA template using primers CP1144 and CP1145, and ligated to pCR-Blunt II-TOPO. This EF1α transcript was selected as a ubiquitous expression control gene for RNAscope experiments due to its high expression in all RNA-seq tissue samples. The EF1α cDNA insert was sequenced using adjacent M13F and M13R primers annealed in the pCR-Blunt II-TOPO vector, and the first approximately 1.1 kb and the last approximately 350 bp of the cDNA were verified to be consistent with predictions from the novel transcriptome.
[0176] [Table 3]
[0177] Venus flytrap genomic DNA was extracted from fresh plant tissue using a CTAB-based method (Murray, MG, & Thompson, WF (1980), Rapid isolation of high molecular weight plant DNA, Nucleic Acids Res, 8(19), 4321-4325). Using this as a template, duplicate fragments covering the genes were amplified by PCR and sequenced using Sanger sequencing. The duplicated and nested primer sets were CP1010 and CP0995, CP0994 and CP1034, CP1033 and CP1035, CP1172 and CP1173, CP1176 and CP1177, and CP1174 and CP1009 (see Table 3). The presence of two overlapping peaks on the chromatogram was used as evidence of heterozygosity and allelic variation. The 3'-most primer (CP1009) annealed across the stop codon and the last 31 bases of the coding sequence, making it impossible to rule out the presence of additional SNPs within this extension. A total of 32 SNPs were detected in the FLYC1 gene, of which only two were found within the coding region and were silent (i.e., coding for the same amino acid).
[0178] For electrophysiological characterization, FLYC1, FLYC2, and OSCA cDNA were synthesized (human codon optimized) and placed into a pIRES2-mCherry vector from Genewiz. The K558E and K579E substitutions in FLYC1 were generated using the Q5 Site-Directed Mutagenesis Kit (New England BioLabs) according to the manufacturer's instructions and confirmed by full-length DNA Sanger sequencing.
[0179] Identification of Drosera capensis cDNA sequences and design of qRT-PCR primers To find Drosera FLYC1 homologs, the first exon of Venus flytrap FLYC1 was blasted against a scaffold assembly of the D. capensis genome (Butts, CT et al., 2016, Proteins, 84(10), 1517-1533, doi:10.1002 / prot.25095). The first exon encodes the most diverse N-terminal cytoplasmic domain among MSL family members, making it the best distinguishing element between different MSL genes and potentially identifying the best FLYC1 homolog. Using this method, four closely related homologous sequences were found (e-value: 0.0; over 60% query coverage; NCBI blastn). Two of these were located at scaffold LIEC01006169.1, one at LIEC01010092.1, and the other at LIEC01012078.1. Positions 42843–46002 of scaffold LIEC01006169.1 (reverse strand; start-to-stop codon) and positions 23270–26408 of scaffold LIEC01012078.1 (forward strand; start-to-stop codon) were predicted to encode transcripts closely resembling the complete Venus flytrap FLYC1 sequence, based on the inferred exon structure and conserved sequences. These genes were named DcFLYC1.1 and DcFLYC1.2, respectively.
[0180] To determine the exact DcFLYC1.1 and DcFLYC1.2 sequences encoded in D. capensis plants, cDNA was amplified using primers predicted to bind at the 5' and 3' UTRs (primers CP1240 and CP1243; and CP1224 and CP1225, respectively). Each cDNA was amplified from two different plant-derived templates, and these PCR products were independently cloned into pCR-Blunt II-TOPO vectors. For DcFLYC1.1, one of the two clones from each of the two reactions from the independent templates, and two of the two clones, shared the same cDNA sequence as determined by Sanger sequencing. For DcFLYC1.2, three of the seven clones from each of the two reactions, and four of the eight clones, shared the same cDNA sequence. The other clones had additional base differences not found in the other clones. These may represent endogenous mutations in this tetraploid species, but they are more likely to be the result of PCR amplification errors or low-fidelity transcription and reverse transcription processes.
[0181] DcFLYC1.1 and DcFLYC1.2 cDNAs share high sequence similarity. To resolve the relationship between the two by qRT-PCR, a primer pair was designed in which one of two primers anneals to the extension of less conserved residues in the 5' or 3' UTR (CP1242 and CP1237, and CP1224 and CP1233, respectively). Degradation of the two cDNAs using these primers was confirmed by directly sequencing the two PCR products by Sanger sequencing. DcFLYC1.1 and DcFLYC1.2 cDNAs were synthesized (human codon optimized) using Genewiz and subcloned into the pIRES2-mCherry vector for electrophysiological characterization.
[0182] To design qRT-PCR primers for the D. capensis EF1α reference transcript, PCR products from a cDNA template were amplified using primers CP1208 and CP1209. Sanger sequencing of these products suggested the presence of at least two very similar EF1α transcripts, as evidenced by double peaks on the chromatogram. These could represent products of different genes or alleles. To avoid bias towards any one EF1α transcript, the qRT-PCR primers were purified and annealed on unambiguous bases (CP1218 and CP1219).
[0183] qRT-PCR Analysis of leaves and tactile hairs of *Drosera rotundifolia* by qRT-PCR was performed using a SYBR green-based protocol. Briefly, cDNA was generated using 500-1000 ng of RNA with the Maxima First Strand cDNA Synthesis Kit (Thermo Fisher), and the resulting dilution was used as a template for qPCR. Comparisons were performed biologically four times. The cycle reaction temperatures were 95°C for 10 seconds, 60°C for 20 seconds, and 72°C for 30 seconds. The change in gene expression ratio was calculated using the ΔΔCt method.
[0184] Bioinformatics analysis: homology modeling, protein / nucleotide comparison, protein topology prediction, and evolutionary history. Unless otherwise specified, all nucleotide and amino acid comparisons were performed using MUSCLE's default settings. For the phylogenetic analysis of the MscS domain and OSCA protein shown in Figures 2A and 2D, maximum likelihood trees were constructed using MEGA X software (LG+G model, 4 separate Gamma categories) from the MUSCLE alignment of the MscS domain (Haswell, ES, & Meyerowitz, EM (2006). MscS-like proteins control plastid size and shape in Arabidopsis thaliana. Curr Biol, 16(1), 1-11. doi:10.1016 / j.cub.2005.11.044) and the full-length OSCA protein, and viewed using iTOL. All locations with site coverage less than 95% were removed (partial deletion option). The tree with the highest log-likelihood and bootstrap value from 1000 replicates is shown in the figure.
[0185] The protein topologies of FLYC1 and FLYC2 (Figures 2B and 2C) were predicted using Protter. The DmOSCA topology (Figure 2E) was determined by aligning the protein to Arabidopsis OSCA1.2 and assigning the TM (transmembrane) domain and pore domain to the same positions identified in the OSCA1.2 protein structure. To model the Venus flytrap FLYC1 TM6 putative pore domain, residues A555-P593 were screwed into residues Q92-F130 of MscS in the closed conformation (PDB2OAU). C7 symmetry was imposed using a Rosetta script, and the side-chain and skeletal conformations were minimized using a Rosetta energy function with the solvation term turned off due to exposed hydrophobicity within the substructure.
[0186] Accession number RNA-Seq data, de novo transcriptome, ORF (open reading frame) identification, and downstream differential gene expression analysis can be found at NCBI and under umbrella Bioproject PRJNA530242 using the accession numbers referenced above. CDS sequences subcloned and sequenced from plant cDNA templates are available at GenBank (DmFLYC1, DcFLYC1.1, and DcFLYC1.2).
[0187] Cell culture and transient transfection with heterologous polynucleotides PIEZO1-knockout human embryonic kidney 293T (HEK-P1KO) cells were used in all heterologous expression experiments. HEK-P1KO cells were prepared using CRISPR-Cas9 nuclease genome editing technology as previously described (Lukacs, V. et al., 2015, Nat Commun, 6, 8329. doi:10.1038 / ncomms9329), and were negative for mycoplasma contamination. Cells were grown in Dulbecco's Modified Eagle Medium (DMEM) containing 4.5 mg / ml-1 glucose, 10% fetal bovine serum, 50 units / ml-1 penicillin, and 50 μg / ml-1 streptomycin. Cells were plated onto 12 mm round glass poly-D-lysine coated coverslips placed in 24-well plates and transfected with lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. All plasmids were transfected at a concentration of 700 ng / ml. Cells were recorded 24–48 hours after transfection.
[0188] Electrophysiology Patch-clamp experiments in cells were performed using an Axopatch 200B amplifier (Axon Instruments) in standard cell attachment or excision patch (inside-out) mode. Current was sampled at 20 kHz and filtered at 2 kHz or 10 kHz. Leakage current before mechanical stimulation was subtracted offline from the current trace. Voltage was not corrected for liquid junction potential (LJP), except in ion selectivity experiments. LJP was calculated using Clampex 10.6 software. All experiments were performed at room temperature.
[0189] solution For cell adhesion patch clamp recording, the external solution used to zero the membrane potential contained KCl:140, MgCl2:1, glucose:10, and HEPES (pH 7.3 with KOH):10 (units: mM). The recording pipette, when filled with a standard solution consisting of NaCl:130 mM, KCl:5, CaCl2:1, MgCl2:1, TEA-Cl:10, and HEPES (pH 7.3 with NaOH):10 (units: mM), had a resistance of 1–3 MΩ.
[0190] Ion selectivity experiments were performed using an inside-out patch configuration. PCl / PNa was measured in an extracellular solution consisting of NaCl:150 and HEPES (pH 7.3 due to NaOH):10 (units: mM), while the intracellular solution consisted of NaCl:30, HEPES:10, and sucrose (pH 7.3 due to NaOH):225 (units: mM). Calcium gluconate solution consisted of calcium gluconate:50, CaCl2:0.5, HEPES:10, and sucrose (pH 7.3 due to NaOH):170 (units: mM).
[0191] mechanical stimulation Macroscopic stretch-activated currents were recorded in inside-out patch clamp configurations attached to or excised from cells. The membrane patches were stimulated with a 1-second negative ultrasound application through the recording electrode using a Clampex controlled pressure clamp HSPC-1 device (ALA-scientific), with a 40-second inter-sweep duration. Stretch-activated single-channel currents were recorded in cell-attached configurations. Since single-channel amplitude is independent of pressure intensity, optimal pressure stimulation was used to induce a response enabling single-channel amplitude measurement. These stimulation values were highly dependent on the number of channels in a given patch of recording cells. Single-channel amplitude at a given potential was measured from trace histograms of 5–10 repeated recordings. Gaussian equations were applied to the histograms using Clampfit 10.6 software. Single-channel gradient conductance for each individual cell was calculated from linear regression curves fitted to single-channel IV plots.
[0192] Permeability measurement The inverted potential for each cell in the aforementioned solution was determined by interpolation of the respective current-voltage data. The transmittance was calculated using the following Goldman-Hodgkin-Katz (GHK) equation. PCl / PNa ratio: TIFF2023549176000007.tif15128
[0193] In situ hybridization and imaging The entire Venus flytrap and the leaves of the Cape sundew were cut from the plants, fresh-frozen in liquid N2, and 15 μm sections were collected. RNA in situ hybridization (RNAscope) was performed on sections according to the manufacturer's instructions (ACDBio:#323100) using probes for DmFLYC1 (ACDBio; reference: 546471, lot: 18177B), DmFLYC1 sense (ACDBio; reference: 566181-C2, lot: 18361A), DmFLYC2 (ACDBio; reference: 546481, lot: 18177C), DmOSCA (ACDBio; reference: 571691, lot: 19032A), DcFLYC1.1 / DcFLYC1.2 (ACDBio; reference: 572451, lot: 19037B), and EF1α (ACDBio; reference: 559911-C2, lot: 18311B). DmFLYC1 sense (Figure 3B) and DmFLYC2 (Figures 9A and 9B) were tested on the same sections. However, the DmFLYC2 probe was tested independently in two additional experiments, and no signal was observed. Slides were quantified using Vectashield+DAPI (reference: H1200, lot: ZE0815). Stained sections were imaged with a Nikon C2 laser scanning confocal microscope, and z-stacks were acquired throughout the entire section using a 60x objective lens. The image shown is the maximum projection of the entire z-stack. Images were processed using ImageJ (Fiji image processing package).
[0194] Immunostaining experiments targeting the bungarotoxin binding sequence (BBS) The labeling efficiency of DmFLYC1 was initially tested with the aim of using similar strategies for DmFLYC2, DmOSCA, and DcFLYC1.1 / 1.2. Protein expression in the membrane can be estimated by inserting a bungarotoxin-binding sequence (BBS) into the putative extracellular loop of the protein of interest, immunolabeling it with α-bungarotoxin conjugated to a fluorescent tag, and measuring the fluorescence efficiency using flow cytometry. A 13-amino acid bungarotoxin-binding sequence (WRYYESSLEPYPD; SEQ ID NO: 41) was cloned using a Q5 site-directed mutagenesis kit at sites G216, P287, V289, or P292 of DmFLYC1-ires mCherry. A PIEZO1-BBS-ires GFP (green fluorescent protein) construct demonstrated to be expressed in the membrane was used as a positive control. HEK-P1 KO cells were transfected with PIEZO1-BBS and FLYC1-BBS constructs. 48 hours after transfection, the culture medium was aspirated, and the cells were resuspended in 100 μL of labeled buffer (PBS containing 2% fetal bovine serum and 1 mM EDTA). Cells were then separated from the plate using Versen. Cells were incubated in 100 μL of labeled buffer with 1:100 Alexa Fluor 647 conjugate α-bungarotoxin for PIEZO1 and Alexa Fluor 488 conjugate α-bungarotoxin for DmFLYC1 (Thermo Fisher Scientific, reference: B13422, reference: B35450) for 15 minutes at room temperature. The cells were then washed three times with labeled buffer, with a 5-minute incubation between steps, and subjected to flow cytometry (LSR II). Labeling efficiency was measured using Flowjo. Positive labeling of PIEZO1-BBS was observed, but labeling of FLYC1 was not observed at four different sites of the two putative extracellular loops of the protein. The insertion of BBS into FLYC1 may have affected the folding and transport of the wild-type protein.
[0195] Example 7: Venus flytrap plants are sensitive to ultrasonic stimulation. In terrestrial plants and green algae, chloride permeable channel openings are associated with membrane depolarization due to the outflow of chloride ions under an electrochemical gradient. To determine whether plants possess mechanosensible chloride channels that can be induced by ultrasonic stimulation, the well-known carnivorous plant Dionaea muscipula (Venus flytrap) was selected for the experiment. The leaves of the Venus flytrap consist of open bilobed traps that attract animal prey (insects) by volatile secretions. When an animal comes into contact with one of the 3-4 mechanosensory hairs on each lobe, the hair bends, generating an action potential in the sensory cells at the base of the hair, which propagates throughout the trap. It closes rapidly with two action potentials within a short 30-second timeframe, trapping the prey. This trap closes in 100 milliseconds, one of the fastest movements in the plant kingdom.
[0196] In Examples 1-6 above, genes selectively expressed in sensory hairs were identified, including two transcripts homologous to the MSL class and one transcript homologous to the OSCA family. One of these three transcripts was highly enriched in mechanosensitive sensory hairs and was named FLYC1 (flycatcher 1). Example 4 above demonstrated that when human codon-optimized FLYC1 was expressed in mechanosensitive, HEK-P1 KO cells (AEDubin et al., 2017, Neuron, 94:266-270, E263), they became sensitive to membrane stretching, thus confirming that this channel is chloride-selective.
[0197] To test the sensitivity of Venus flytrap plants to ultrasonic stimulation, plants were attached to lithium niobate transducers to allow delivery of ultrasonic stimuli at different frequencies, and the plant responses were monitored. The plant traps were found to close when at least two pulses of ultrasonic stimulation above 1 MPa were delivered within 30 milliseconds (Figures 16A and 16B). These data confirmed that ultrasonic stimulation may induce mechanesensory hairs, leading to closure.
[0198] Example 8: Exogenous expression to establish FLYC1 as a candidate sonosilence channel As described above, FLYC1 is a chloride-selective mechanosensible protein highly concentrated in Venus flytrap sensory hairs. Immortalized rat pancreatic beta cell line (INS1) (I. Cosar-Castellano et al., 2008, Diabetes, 57:3056-3068) were used to express GCaMP6 (TWChen et al., Nature, 499:295-300), a genetically encoded calcium indicator. These cells exhibited spontaneous calcium events, as measured by changes in GCaMP6 fluorescence. INS1 cells expressing heterologous FLYC1 polypeptide were transduced using a human codon-optimized polynucleotide sequence encoding the FLYC1 polypeptide. INS1 cells expressing heterologous FLYC1 polypeptide were found to exhibit reduced spontaneous response after ultrasound stimulation (Figures 17A and 17B). In addition, the morphology of INS1 cells was not altered by FLYC1 changes or ultrasound stimulation. The results of these experiments suggest that the FLYC1 polypeptide may function as a sonosilencing channel when expressed as a heterologous protein in other cell types, such as INS1 cells.
[0199] Example 9: Fluorescence Imaging Plate Reader Membrane Potential Assay Using a plate reader-based fluorescence imaging plate reader (FLIPR) membrane potential assay (FMP assay), we confirmed that the FLYC1 polypeptide functions as an ion channel when expressed as a heterologous (or exogenous) polypeptide in a given cell. The FMP (FLIPR membrane potential) kit provides a unique assay developed by Molecular Dynamics for use in GPCR (G protein-coupled receptor) and ion channel discovery by those skilled in the art. INS1 cells, molecularly engineered to express heterologous FLYC1 polypeptide, were cultured in a 96-well plate. FMP dye (FLIPR membrane potential dye) was added to the wells, and baseline (t=0) read values were obtained from the plate reader. Different amounts of potassium chloride were added to the wells, and changes in FMP (FLIPR membrane potential) fluorescence were monitored every 5 minutes for up to 20 minutes. Consistent with the manufacturer's handbook, a dose-dependent increase in fluorescence was observed with a peak response of approximately 2.5-fold change for 60 mM KCl. INS1 cells expressing heterologous FLYC1 polypeptide showed a lower response to KCl stimulation (Figures 18A and 18B). Figures 17A, 17B, 18A, and 18B also demonstrate that heterologously expressed FLYC1 in INS-1 cells can suppress INS-1 cell activity and reduce insulin secretion.
[0200] Example 10: Sonosilencing Features To determine the sonosilencing properties of exogenously expressed FLYC1 polypeptide in HEK cells, each cell expressing a heterologous FLYC1 polypeptide was maintained at +60 mV, and various ultrasonic pulse durations were delivered to the cells using a 6.91 MHz transducer. Since the equilibrium potential of chloride is approximately -70 mV, the cells were maintained at +60 mV to observe the maximum hyperpolarization response. Ultrasonic stimuli were delivered to the cells using a lithium niobate transducer. HEK cells expressing FLYC1 polypeptide were found to respond variably to ultrasonic stimuli of different durations while the intensity was kept constant (2 MPa). In addition, HEK cells expressing FLYC1 polypeptide were observed to show some voltage dependence in the depolarization membrane potential (Figure 19). As demonstrated in Figure 19, FLYC1 expressed in INS-1 cells was able to inhibit excitatory cells.
[0201] Example 11: Calcium imaging analysis Using calcium imaging, we evaluated whether intracellularly expressed FLYC1 polypeptide could suppress the ultrasound activation of hsTRPA1. These experiments employed imaging techniques in which an ultrasound transducer was aligned with a cell culture dish holder, and changes in the cellular response were recorded as changes in GCaMP fluorescence. While not intended to be theoretically constrained, since the ultrasound activation of hsTRPA1 requires amplification from membrane-bound calcium channels, it was expected that co-introduction of chloride ions via FLYC1 polypeptide expression would attenuate this response. The results showed that intracellular expression of FLYC1 polypeptide consistently suppressed ultrasound (US) induction, rather than the AITC-activated TRPA1 response (Figures 20A and 20B). AITC is a chemical agonist that activates TRPA1 via an ultrasound-independent mechanism. (M. Raisinghani et al., 2011, J. Physiol Cell Physiol, 301:C587-600 and M. Duque et al., 2020, bioRxiv:2020.2010.2014.338699.) As established by Figures 20A and 20B, the expression of exogenous FLYC1 polypeptide is inhibited by suppressing ultrasound-induced activation in hsTRPA1-expressing cells.
[0202] In addition, an R334E variant of the FLYC1 polypeptide was identified that, when expressed in cells (e.g., HEK-P1KO cells (Figures 21A and 21B)), exhibits a slower inactivation kinetic in response to membrane stretching. The R334E FLYC1 variant polypeptide sequence is provided in SEQ ID NO: 42. It was confirmed that expression of the FLYC1 variant polypeptide in cells can modify the FLYC1 polypeptide to obtain channels exhibiting different functional characteristics.
[0203] Other Embodiments From the above description, it will be clear that various forms and embodiments can be modified and adapted to suit various uses and conditions, as described herein. Such implementations are also within the scope of the following claims.
[0204] Any definition of a variable in this specification includes a list of elements, which includes the definition of that variable as any single element or as a combination (or subcombination) of the enumerated elements. Descriptions of embodiments in this specification include those embodiments as any single embodiment or in combination with any other embodiment or part thereof.
[0205] All publications, patents, and patent applications referenced herein are incorporated by reference to the same extent as each individual patent and publication is specifically and individually indicated as being incorporated by reference.
Claims
1. 1. A method for inducing influx or efflux of cations or anions in a cell, comprising the steps of: expressing in said cell a heterologous mechanosensory polypeptide selected from the group consisting of DmFLYC1, DcFLYC1.1, DmOSCA, DmFLYC2, and DcFLYC1.2, or variants thereof; and applying ultrasound to the cells, thereby inducing an influx or efflux of cations or anions in the cells.
2. The method of claim 1 , wherein the cells are sensitized to mechanical deformation or stretching caused by ultrasound.
3. The application of ultrasonic waves and / or, effecting a change in mechanosensory polypeptide conductance in said cells to modulate cellular activity and / or function; Inducing anion influx or efflux in said cells, inducing anion influx that inhibits or suppresses the activity and / or function of said cells, or inducing anion efflux that evokes or stimulates the activity and / or function of said cells; The method according to claim 1 or 2.
4. The polypeptide comprises a sequence having at least 90% or at least 95% sequence identity to a polypeptide sequence selected from SEQ ID NOs: 5, 42, 11, 7 or 13; or The polypeptide is encoded by a sequence having at least 90% or at least 95% sequence identity to a polynucleotide sequence selected from SEQ ID NOs: 6, 12, 8, or 14; The method of claim 1.
5. the polypeptide is DmOSCA, The polypeptide comprises a sequence having at least 90% or at least 95% sequence identity to SEQ ID NO:9, or The polypeptide is encoded by a polynucleotide sequence having at least 90% or at least 95% sequence identity to SEQ ID NO: 10; The method according to any one of claims 1 to 3.
6. 1. A method for initiating or inducing a cellular response to ultrasonically induced mechanical deformation or stretch to modulate cellular activity and / or function, comprising the steps of: (a) transducing a cell to express a heterologous mechanosensory polypeptide selected from DmFLYC1, DcFLYC1.1, DmOSCA, DmFLYC2, and DcFLYC1.2 or a variant thereof; (b) applying ultrasound to the cells; and (c) inducing an influx or efflux of cations or anions and changes in cellular activity and / or function in cells expressing said mechanosensory polypeptide following application of said ultrasound, thereby initiating or inducing a cellular response to mechanical deformation or stretch caused by ultrasound to modulate cellular activity and / or function.
7. The polypeptide comprises a sequence having at least 90% or at least 95% sequence identity to a polypeptide sequence selected from the group consisting of SEQ ID NOs: 5, 42, 11, 7, and 13; or The polypeptide is encoded by a sequence having at least 90% or at least 95% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NOs: 6, 12, 8 and 14; The method according to claim 6.
8. the polypeptide is DmOSCA, The polypeptide comprises a sequence having at least 90% or 95% sequence identity to SEQ ID NO:9, or The polypeptide is encoded by a polynucleotide sequence having at least 90% or 95% sequence identity to SEQ ID NO:
10. The method according to claim 6.
9. 9. The method of any one of claims 1 to 8, wherein the polypeptide is encoded by a polynucleotide sequence that is codon-optimized for expression in mammalian or human cells and is non-naturally occurring.
10. 10. The method of any one of claims 1 to 9, wherein the polypeptide is expressed in the cell following transduction of the cell with a plasmid or viral vector comprising a polynucleotide sequence encoding the polypeptide.
11. 11. The method of claim 10, wherein the cells are transduced by a viral vector selected from a lentiviral vector or an adeno-associated viral (AAV) vector.
12. The method according to any one of claims 1 to 11, wherein the cell is one or more of a muscle cell, a cardiac muscle cell, an insulin secreting cell, a pancreatic cell, a kidney cell, a neuronal cell or a plant cell.
13. the ultrasound has a frequency of about 0.2 MHz to about 20 MHz; and / or the ultrasound has a focal zone of about 1 cubic millimeter to about 1 cubic centimeter; The method according to any one of claims 1 to 12.
14. The method of any one of claims 1 to 13, further comprising the step of contacting the cells with microbubbles prior to applying ultrasound.
15. the cell is in vitro, ex vivo, or in vivo; and / or The cell is in a mammalian subject, a human subject, or a plant. The method according to any one of claims 1 to 14.
16. The ultrasound is generated using a photoacoustic system or transducer; and / or The ultrasonic waves are generated using a lead zirconate titanate (PZT) transducer. The method according to any one of claims 1 to 15.
17. A plasmid or viral vector comprising a polynucleotide encoding a mechanosensory polypeptide selected from DmFLYC1, DcFLYC1.1, DmOSCA, DmFLYC2, DcFLYC1.2, or a variant thereof.
18. 18. The plasmid or viral vector of claim 17, wherein the viral vector is a lentiviral vector or an adeno-associated viral (AAV) vector.
19. The polypeptide comprises a sequence having at least 90% or at least 95% sequence identity to a polypeptide sequence selected from the group consisting of SEQ ID NOs: 5, 42, 11, 9, 7, and 13; or The polypeptide is encoded by a sequence having at least 90% or 95% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NOs: 6, 12, 10, 8, and 14; A plasmid or viral vector according to claim 17 or 18.
20. A cell comprising the plasmid or viral vector of any one of claims 17 to 19, or a heterologous gene sequence encoding a polypeptide selected from the group consisting of DmFLYC1, DcFLYC1.1, DmOSCA, DmFLYC2, DcFLYC1.2, or variants thereof.
21. 21. The cell of claim 20, which is one or more of a muscle cell, a cardiac muscle cell, an insulin-secreting cell, a pancreatic cell, a kidney cell, a neuronal cell or a plant cell.
22. (i) the polypeptide is DmFLYC1 and comprises a sequence having at least 90% or at least 95% sequence identity to SEQ ID NO:5 or SEQ ID NO:42; or The polypeptide is encoded by a polynucleotide sequence having at least 90% or at least 95% sequence identity to SEQ ID NO:6; (ii) the polypeptide is DcFLYC1.1 and comprises a sequence having at least 90% or at least 95% sequence identity to SEQ ID NO: 11, or the polypeptide is encoded by a polynucleotide sequence having at least 90% or at least 95% sequence identity to SEQ ID NO: 12; (iii) the polypeptide is DmOSCA and comprises a sequence having at least 90% or at least 95% sequence identity to SEQ ID NO:9, or the polypeptide is encoded by a polynucleotide sequence having at least 90% or at least 95% sequence identity to SEQ ID NO:10; (iv) the polypeptide is DmFLYC2 and comprises a sequence having at least 90% or at least 95% sequence identity to SEQ ID NO:7; or the polypeptide is encoded by a polynucleotide sequence having at least 90% or at least 95% sequence identity to SEQ ID NO:8; or (v) the polypeptide is DcFLYC1.2 and comprises a sequence having at least 90% or at least 95% sequence identity to SEQ ID NO: 13, or the polypeptide is encoded by a polynucleotide sequence having at least 90% or at least 95% sequence identity to SEQ ID NO: 14; A plasmid or vector according to claim 17 or a cell according to claim 20.
23. An isolated polynucleotide encoding a mechanosensory polypeptide or variant thereof selected from the group consisting of DmFLYC1, DcFLYC1.1, DmOSCA, DmFLYC2 and DcFLYC1.
2.
24. 24. A mechanosensory polypeptide encoded by the isolated polynucleotide of claim 23.
25. 24. A plasmid or viral vector comprising the isolated polynucleotide of claim 23.
26. A cell comprising the isolated polynucleotide of claim 23.
27. A cell expressing the mechanosensory polypeptide of claim 24.
28. A composition comprising a cell according to claim 26 or 27.
29. 30. The composition of claim 28, further comprising a pharma- ceutically acceptable carrier, excipient, or diluent.
30. the polypeptide is DmFLYC1 or a variant thereof, The DmFLYC1 polypeptide comprises or consists essentially of the sequence SEQ ID NO:5 or SEQ ID NO:42, or The DmFLYC1 polypeptide is encoded by a polynucleotide sequence comprising or essentially consisting of SEQ ID NO:6; The method according to claim 1 or 5.
